The contribution of de novo coding mutations to meningomyelocele

- 3
- 4

5 6 Yoo-Jin Ha^{1,2,3}, Isaac Tang^{1,2}, Ashna Nisal^{1,2}, Ishani Jhamb^{1,2}, Cassidy Wallace^{1,2}, Sarah Schroeder^{1,2}, Chanjae Lee⁴, Keng loi Vong^{1,2}, Naomi Meave^{1,2}, Fiza Jiwani^{1,2}, Chelsea 7 Barrows^{1,2}, Sangmoon Lee^{1,2}, Nan Jiang^{1,2}, Arzoo Patel^{1,2}, Francisco A. Blanco⁵, 8 Seyoung Yu⁶, Hui Su Jeong^{1,2,7}, Isaac Plutzer⁸, Michael B. Major⁸, Béatrice Benoit⁹, 9 Christian Poüs^{9,10}, Caleb Heffner¹¹, Zoha Kibar¹², Gyang Markus Bot¹³, Hope Northrup¹⁴, 10 Kit Sing Au¹⁴, Madison Strain¹⁵, Allison Ashley-Koch¹⁵, Richard H. Finnell¹⁶, Joan T. 11 Le¹⁷, Hal Meltzer¹⁷, Camila Araujo¹⁸, Helio R. Machado¹⁸, Roger E. Stevenson¹⁹, Anna 12 Yurrita²⁰, Sara Mumtaz²¹, Osvaldo M. Mutchinick²², José Ramón Medina-Bereciartu²³, 13 Friedhelm Hildebrandt²⁴, Gia Melikishvili²⁵, Rony Marwan²⁶, Valeria Capra²⁷, Mahmoud 14 M. Noureldeen²⁸, Aida M.S. Salem²⁸, Mahmoud Y. Issa²⁹, Maha S. Zaki²⁹, Ji Eun Lee⁷, 15 Anna Alkelai³⁰, Alan R. Shuldiner³⁰, Stephen F. Kingsmore¹, Stephen A. Murray¹¹, Heon 16 Yung Gee⁶, W. Todd Miller^{31,32}, Kimberley F. Tolias⁵, John B. Wallingford⁴, Spina 17 Bifida Sequencing Consortium*^, Sangwoo Kim^{3,#}, Joseph G. Gleeson^{1,2#^} 18 19 20 ¹Rady Children's Institute for Genomic Medicine, San Diego, CA 92123, USA 21 ² Department of Neurosciences and Pediatrics, University of California, San Diego, CA 92037, 22 USA 23 ³ Department of Biomedical Systems Informatics and Graduate School of Medical Science, Brain 24 Korea 21 Project, Yonsei University College of Medicine, Seoul 03722, Republic of Korea 25 ⁴ Dept. of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA 26 ⁵ Dept. Neuroscience, Biochemistry and Molecular Biology, Baylor College of Medicine, 27 Houston, TX 77030, USA 28 ⁶ Department of Pharmacology and Graduate School of Medical Science, Brain Korea 21 Project, 29 Yonsei University College of Medicine, Seoul 03722, Republic of Korea 30 ⁷ Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 31 06351, Republic of Korea 32 ⁸ Department of Cell Biology and Physiology, Washington University in St. Louis, MO 63110 33 ⁹ INSERM UMR-S 1193, UFR de Pharmacie, University Paris-Saclay, UFR de Pharmacie, Orsay 34 91400. France. 35 ¹⁰ Biochimie-Hormonologie, Assistance Publique - Hôpitaux de Paris Université Paris-Saclay, 36 Clamart 92140, France 37 ¹¹ The Jackson Laboratory, Bar Harbor, ME 04609, USA 38 ¹² Department of Neurosciences, Research Center of CHU Sainte Justine, University of Montreal, 39 Montreal, H3T 1C5, Canada 40 ¹³ Neurosurgery Division, Department of Surgery, Jos University Teaching Hospital, Jos 930103, 41 Nigeria 42 ¹⁴ Department of Pediatrics, McGovern Medical School at the University of Texas Health Science 43 Center at Houston and Children's Memorial Hermann Hospital, Houston, TX 77030, USA 44 ¹⁵ Molecular Physiology Institute, Duke University Medical Center, Durham, NC 27710, USA 45 ¹⁶ Center for Precision Environmental Health, Departments of Molecular and Human Genetics,

- 45 Center for Precision Environmental Health, Departments of Molecular and Human Genetics,
- 46 Molecular and Cellular Biology and Medicine, Baylor College of Medicine, Houston 77030, TX,
 47 USA
- 48 ¹⁷ Rady Children's Hospital, San Diego, CA 92123, USA

- 49 ¹⁸ Department of Surgery and Anatomy Ribeirão Preto Medical School University of São Paulo,
- 50 Ribeirao Preto SP 14015-068, Brazil
- 51 ¹⁹ J.C. Self Research Institute of Human Genetics, Greenwood Genetic Center, Greenwood, SC
- 52 29646, USA
- 53 ²⁰ Catedrática de Ciencias Ómicas, Facultad de Medicina, Universidad Francisco Marroquín,
- 54 01001, Guatemala
- 55 ²¹ National University of Medical Sciences, Rawalpindi 44000, Pakistan
- 56 ²² Department of Genetics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
- 57 Mexico City 14080, Mexico
- 58 ²³ Clínica Santa Sofia, Caracas 1061, Venezuela
- ²⁴ Division of Nephrology, Boston Children's Hospital, Boston, MA 02115, USA
- 60 ²⁵ Department of Pediatrics, MediClubGeorgia Medical Center, Tbilisi, 0160, Georgia
- 61 ²⁶ Division of Pediatric Surgery, University of Colorado School of Medicine, Children's Hospital
- 62 of Colorado, Colorado Fetal Care Center, Aurora, CO, 80045, USA
- 63 ²⁷ Genomics and Clinical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa 16147, Italy
- ²⁸ Department of Pediatrics, Faculty of Medicine, Beni-Suef University, Beni-Suef 62521, Egypt
- 65 ²⁹ Clinical Genetics Department, Human Genetics and Genome Research Division, National
- 66 Research Centre, Cairo 12311, Egypt
- ³⁰ Regeneron Genetics Center, Tarrytown, NY 10591, USA
- ⁶⁸ ³¹ Department of Physiology and Biophysics, Stony Brook University, Stony Brook, NY 11794,
- 69 USA
- 70 ³² VA Medical Center, Northport, NY 11768, USA
- 71
- 72 # Co-corresponding authors
- 73 *Consortium membership in appendix
- 74 ^ Contact PI for consortium: Joseph G. Gleeson
- 75 Keywords: Meningomyelocele, spina bifida, neural tube defect, de novo mutation, penetrance,
- 76 expressivity, trio, exome, protein-interaction network, congenital, hydrocephalus.
- 77 Abstract word count: 158
- 78 Text word Count: 2877
- 79 Number of Figures: 4
- 80 Number of Tables: 1
- 81 Number of Supplementary Figures: 16
- 82

84 Abstract

85 Meningomyelocele (MM) is considered a genetically complex disease resulting from 86 failure of neural tube closure (NTD). Patients display neuromotor disability and frequent 87 hydrocephalus requiring ventricular shunting. A few proposed genes contribute to disease 88 susceptibility, but most risk remains unexplained¹. We postulated that de novo mutations (DNMs) under purifying selection contribute to MM risk². Here we recruited a cohort of 89 90 851 MM trios requiring shunting at birth, compared with 732 control trios, and found that 91 de novo likely gene disrupting or damaging missense mutations occur in approximately 92 22.3% of subjects, 28% of which are estimated to contribute to disease risk. The 187 93 genes with damaging DNMs collectively define networks including actin cytoskeleton 94 and microtubule-based processes, axon guidance, and histone modification. Gene 95 validation demonstrates partial or complete loss of function, impaired signaling and 96 defective neural tube closure in *Xenopus* embryos. Our results suggest DNMs make key 97 contributions to MM risk, and highlight critical pathways required for neural tube closure 98 in human embryogenesis.

99

100 **Main**

101 MM, also known as spina bifida, is the most common central nervous system 102 (CNS) structural defect in humans. MM results from failed closure of the neural tube in 103 the first six weeks of gestation. While folic acid supplementation has reduced disease 104 burden³, the incidence of 1:3000–10,000 live-births, along with the associated lifelong 105 neuromotor disability and increased mortality, has focused attention on this condition. 106 Timely diagnosis allows for prenatal counseling and informed management choices, 107 including termination of pregnancy, fetal surgery, or postnatal surgery for the nearly fully 108 concordant hydrocephalus accompanying the hindbrain Chiari type II malformation^{4,5}. 109 Over 20 million people worldwide live with an NTD yet causes remain poorly defined.

110 Mouse knockout studies established hundreds of genes associated with NTD, 111 often with partial penetrance, implicating apical-basal polarity, Wnt/PCP, Wnt/betacatenin, and DNA transcription pathways⁶. Despite epidemiological heritability estimates 112 113 of 60-70% for NTDs⁷, few genes are implicated in human NTDs, potentially due to 114 genetic heterogeneity. Additive effects of common SNPs have been proposed, especially in the folate metabolism gene MTHFR (C677T, p.Ala222Val), but meta-analysis from 22 115 different association studies suggest only a modest risk (OR 1.23, 95% CI: 1.07–1.42)⁸. 116 117 Inherited mutations in VANGL1/2, TBXT, CCL2, CELSR1 were identified in cohort 118 studies⁹⁻¹², but represent only a few percent of cases. Prior successes in de novo mutation 119 (DNM) approaches in conditions like autism and congenital heart disease, where mutations are potentially under purifying selection^{13,14}, prompted a trio approach in 43 120

121 families, identifying recurrent mutations in *SHROOM3*¹⁵, but left unanswered whether 122 larger studies would be better powered.

122

124 Establishing the Spina Bifida Sequencing Consortium

125 A critical step in DNM discovery is assessment for an excess burden of damaging

126 mutations in cases vs. controls¹³. With the conservative assumptions of a modest increase

- 127 in damaging DNMs in cases and estimating perhaps 50–100 total MM genetic risk loci,
- 128 we calculated that a cohort of 300–500 trios would be required to identify 5–10
- 129 recurrently mutated genes (see Supplementary Information and Extended Data Fig.

130 1). In 2015, we thus established the Spina Bifida Sequencing Consortium (SBSC) to 131 aggregate prior CDC (Centers for Disease Control and Prevention, USA)-supported trio 132 recruitment efforts, alongside targeted new recruitment from specialists in more than 12 133 countries, and through social media outreach. Recruitment was limited to diagnosis of 134 MM probands with open neural tissue observed at birth and hydrocephalus requiring 135 shunting, specifying the most severe form of MM compatible with long term survival 136 (Methods). Our ethnically diverse cohort was designed specifically to assess risk from 137 DNMs using trio sequencing, matched with 732 control trios from the Simons Simplex 138 Collection¹⁶. After five years of recruitment, we had enrolled 325 trios, performed trio 139 whole exome sequencing (WES) and DNM analysis, but found no recurrently mutated 140 genes, so we extended the recruitment timeline for an additional five years, to double the 141 cohort size.

After 10 years of recruitment, we assembled a cohort of 851 MM trios (839 trios and 6 quartets) consisting of exome sequence data of 2,541 individuals. SBSC was populated by 15 different worldwide sites, incorporating both historic CDC-assembled cohorts and an aggregated earlier report of 39 NTD trios (35 trios and 2 quartets)¹⁵.

146

147 Excessive damaging DNM burden in MM trios

148 After a series of strict quality controls and kinship analyses applied to trio exomes, we 149 constructed a high-confidence call set of 2,592 DNMs (1,458 from 777 MM trios, and 150 1,134 from 725 control trios) (Methods), and confirmed strong DNM signatures¹⁷ 151 (Extended Data Fig. 2a-2b). The rates of the total and functionally categorized DNMs 152 (LGD: likely gene disrupting, D-Mis: damaging missense, tolerant missense, and 153 synonymous) were calculated for the jointly covered consensus regions (Fig. 1a), 154 wherein total DNM rates lie in a Poisson distribution (Extended Data Fig. 2c-2d, 155 **Methods**). The average mutation rates of total DNMs were 1.22×10^{-8} (1.13×10^{-8} -1.31 $\times 10^{-8}$, 95% CI) in MM and 1.18×10^{-8} (1.09×10^{-8} – 1.28×10^{-8} , 95% CI) in controls, 156 which did not differ significantly (Extended Data Fig. 2e, Wilcoxon rank-sum test P 157 158 value: 0.56), and were also comparable to the rates from previous studies (1.08×10^{-8}) 159 1.32×10^{-8})^{18,19}.

160 In contrast, we observed an excessive rate of LGD DNMs (frameshift Indels, 161 stop-gained, and splice donor/acceptor mutations) in MM (1.2×10^{-9}) compared to controls (5.0×10^{-10}) (Fig. 1b), with a ratio of the two Poisson rates (or rate ratio)²⁰ of 162 2.10 (P value: 9.0×10^{-6}). Case-control comparison of DNM rate per proband (i.e. 163 164 theoretical rate: 0.12 in MM vs. 0.05 in controls, see Methods), suggested that 7.2% 165 (95% CI: 2.96%–11.36%) of MM probands display LGD DNM implicated in MM risk (Table 1). Based upon the excessive burden, approximately 52.43% of LGD DNMs in 166 167 MM probands was estimated to contribute to MM risk (Methods), comparable with rates 168 in other complex diseases such as Tourette ($\sim 51.3\%$) and autism spectrum disorders 169 $(\sim 42\%)^{13,21}$. When LGD DNMs were considered alongside D-Mis DNMs (i.e. LGD + D-170 Mis; referred to as 'damaging DNMs'), 28.26% (95% CI: 7.75%-48.76%) were linked to 171 MM risk with excessive burden. Of note, a subset of high confidence D-Mis DNMs 172 (referred to as 'D-Mis-HC') based upon pathogenicity prediction, conferred 173 approximately 80% of the total LGD risk burden (rate ratio: 1.86, P value: 2.0×10^{-6}). Paternal and maternal ages, expected to be correlated with DNM occurrence^{22,23}, were not 174

correlated with the excessive DNMs burden (Extended Data Fig. 3a). Moreover, there
was no enrichment in tolerant and synonymous missense DNMs.

177 In 3,060 genes considered to be highly constrained (i.e. the probability of loss-of-178 function intolerance: $pLI \ge 0.9$), the burden of D-Mis DNMs appeared even more 179 significant (rate ratio: 2.10, P = 0.003) (**Fig. 1c**). Furthermore, we observed a 180 substantially increased burden of D-Mis-HC DNMs (rate ratio: 7.7, P = 0.002). This 181 contrasts with the DNM contributions of other complex diseases, where LGDs play 182 outsized roles compared with D-Mis DNMs¹³.

183 To assess whether there is major missed heritability using WES compared with 184 whole genome sequencing (WGS), we recruited an additional 101 trios and 1 quartet, and 185 performed WGS using standard discovery pipelines (Methods). We identified nonrecurrent de novo SNV/Indels at expected rates of 1.72×10^{-8} (vs. 1.2×10^{-8} – 2.4×10^{-8} in 186 187 previous publications^{19,24}, see Extended Data Table 1), encompassing 9 putative splice-188 disrupting and 41 in putative enhancer/promoter regions (Supplementary Data). Copy 189 number variant (CNV) analysis revealed two nonrecurrent deletions and two duplications 190 (> 100kb), a rate comparable to other complex diseases^{25,26} (Extended Data Fig. 3b and 191 Extended Data Table 2). De novo inversions or translocations were not observed. In 192 contrast, a high LGD rate (0.13 per proband) in coding region was replicated in WGS, 193 with three overlapping genes observed in the WES cohort (KDM1A, ITPR3, and 194 GRHL2). Overall, WGS-based analysis mirrored the findings from WES and did not 195 identify an additional major class of mutation (see Supplementary Information).

196

197 Functional convergence of DNM genes in MM

198 Out of 198 damaging DNMs (82 LGD and 116 D-Mis) found in MM trios, Sanger 199 sequencing was conducted in 86% (170 out of 198) where sufficient DNA was available, 200 yielding 96.5% validation rate, which removed six false DNMs. The remaining 192 201 damaging DNMs (79 LGD and 113 D-Mis) occurred in 187 unique genes, with only five 202 genes mutated in two separate trios (referred to as 'doubleton'; PAX3, IRS1, ZSWIM6, 203 BRSK2, and VWA8) (Fig. 2a and Supplementary Data). Notably, only PAX3 was 204 previously implicated in human NTDs^{15,27}. Among genes identified as singletons, only 205 TBXT (splice donor) and CELSR1 (frameshift) were previously implicated as inherited NTD risk factors^{9,11}. The lack of additional recurrently mutated genes underscores a 206 significant gap in our current understanding of MM genetic risk factors. 207

Spatial transcriptomic analysis of 36 of the damaging DNM genes confirmed
expression at mouse embryonic day 10.5 coinciding with neural tube closure (MERFISH,
see Methods, Extended Data Fig. 4). We found that most genes were expressed broadly
in the embryo (86%, 31 out of 36), but a minority (14%) showed some cell type specific
expression such as *Celsr1* in neural progenitors and *Stab1* in neural crest progenitors
(Extended Data Fig. 5, Supplementary Information).

214 We next studied the protein interactions of MM DNM genes using the STRING 215 database²⁸ (**Fig. 2b**). Among the 187 genes, 107 (57%) including 4 doubletons, 33 LGDs, 216 and 74 D-Mis were highly interconnected, compared to controls (38% interconnected) 217 (**Extended Data Fig. 6**). Bootstrap analysis confirmed a significantly greater degree of 218 network colocalization than genes in the control group (**Fig. 2c, Methods**, two-sided 219 Wilcoxon rank-sum test, *P* value < 1.0×10^{-16}). Genes exhibiting a higher node degree (*n* 220 ≥ 6) were predominantly observed in the MM gene set (Wilcoxon rank-sum test, one-

sided) (Fig. 2d). Indeed, MM DNM genes were significantly enriched in biological
pathways such as morphogenesis of polarized epithelium, neuronal cell adhesion, neural
tube closure, and signal transduction (Gene Ontology biological processes, adjusted *P*values < 0.05) (Fig. 2e and Extended Data Table 3), suggesting functional convergence
in neural tube closure.

226

227 DNMs implicate functional modules in neural tube closure

228 Using the 187 MM DNM genes as seeds, we employed network propagation to construct 229 a comprehensive gene network associated with human MM risk (Extended Data Fig. 7, 230 see Methods)²⁹, by implicating functionally related genes that might not be directly 231 observable in patients due to, for instance, lethal mutations. The propagated network 232 'Meningomyel-ome' comprised 439 genes, including 257 propagated genes, and 233 exhibited 2.447 interconnected edges. We found an over-representation of 374 234 experimentally proven mouse NTD causal genes³⁰ (Supplementary Data) in both seed 235 and propagated genes (11 and 17 of the mouse NTD genes in before- and after 236 propagation, one-tailed hypergeometric *P* value: 0.0015), corroborating functional 237 relatedness to human MM. In contrast, no such relatedness was found with propagation in 238 genes carrying DNMs in control trios (P value: 0.295).

239 Applying a clustering algorithm³¹ to the 'Meningomyel-ome', we identified five 240 subnetworks in which damaging DNMs and propagated genes were closely connected 241 and enriched within predefined signaling pathways (referred to as submodules): 242 RHO/RAC1 GTPase based actin cytoskeleton organization, microtubule-based process, 243 neuronal migration and axon guidance, metabolism of lipids, and histone modification $(FDR < 10^{-5}, Fig. 3a, see Methods)^{6,32-38}$, suggesting that disrupting these pathways can 244 245 increase MM risk. Notably, a higher haploinsufficiency of the 51 propagated genes 246 within the submodules (pLI = 0.98 vs. 0.69 of 46 seed genes in median, see Extended Data Fig. 8) substantiated the utility of network propagation to further implicate 247 248 potentially lethal MM risk genes.

Common among the twelve most strongly associated signaling pathways with FDR below 10⁻⁸ was actin and microtubules organization processes (**Fig. 3b**). Functional relatedness to other submodules of higher-level processes^{39,40} and essential roles in the neural fold adhesion and closure^{41,42} suggest that RHO/RAC1 GTPase-mediated actin and microtubule organization processes contribute to human MM risk.

254

255 Functional validation of candidate MM genes

We next performed functional assessment of candidate MM DNM alleles or genes. Seven 256 257 genes—TNK2, TIAM1, PLCE1, BRSK2, CLIP2, VWA8, and WHAMM—were selected by 258 their relevance to the RHOA/RAC1/CDC42-mediated actin and microtubule 259 polymerization, five of which are direct regulators (Fig. 4a, Methods). Patient mutations 260 in these genes were all D-Mis DNMs usually in regulatory domains predicted to interfere 261 with protein function, except for LGD mutation in WHAMM predicted to truncate the 262 protein. TNK2 is a CDC42-activated kinase that phosphorylates WASP among other 263 targets. We found that immunoprecipitated TNK2 p.P186L DNM had approximately 264 60% reduced kinase activity to a WASP pseudo substrate, as benchmarked against 265 wildtype and kinase-dead versions (Fig. 4b and Extended Data Fig. 9). TIAM1 is a Src-266 activated RAC1-specific guanine nucleotide exchange factor that promotes filamentous

267 actin (F-actin) assembly. We found that wild type TIAM1 but not the TIAM1 p.H1149P 268 DNM co-localized with filamentous actin (Fig. 4c-d). While basal Rac1 activation was 269 unperturbed, p.H1149P showed significant reduction in Rac1 activation following co-270 expression with constitutively activate Src (Fig. 4e and Extended Data Fig. 10). VWA8 271 is a recurrently mutated mitochondrial matrix-targeting ATPase. We found that the 272 p.R230G proband mutation failed to produce VWA8 protein evidenced on Western blot 273 when transfected in HEK293T cells (Extended Data Fig. 11). Assessment of CLIP2, 274 BRSK2 and PLCE1 MM proband mutations did not report robust defective protein 275 function in standard assays (Extended Data Fig. 12-14). Interestingly the DNM 276 mutations showing impaired protein function have previously been directly or indirectly 277 linked to NTDs in animal models (see **Supplementary Information**). Thus, half of the 278 six missense mutations showed clear disrupted function, consistent with our predicted 279 rate of DNMs contributing to MM risk (52.43% of LGD, and 28.26% of damaging 280 DNMs).

281 An LGD mutation found in WHAMM was selected for in vivo functional 282 assessment in a Xenopus laevis neural tube closure model. Splice-blocking morpholino 283 (MO) of the orthologous Whamm protein (Methods) resulted in dose-dependent NTDs 284 (Fig. 4f-h). Specifically, injection of 5 ng of MO led to mild NTD, while 10 ng injection 285 resulted in more severe open NTD in both anterior and posterior regions, as evidenced by 286 pax3 in situ hybridization, and was rescued by expression of wildtype Whamm 287 (Extended Data Fig. 15). These findings confirm the role of at least one of the DNM 288 genes in MM pathogenesis in vivo and underscore potential gene dosage effects 289 contributing to MM risk.

290

291 Expanding clinical phenotypes to include MM

292 We noted that 82 of the MM DNM genes were previously implicated in syndromic or 293 nonsyndromic phenotypes in the Online Mendelian Inheritance in Man (OMIM) database 294 ⁴³, raising the question of whether our MM subjects might also express some of these 295 OMIM phenotypes. By recontacting families, we found that 6% (5 out of 83) of the MM 296 subjects (i.e. with mutations in ZSWIM6, PAX3 in two subjects, TCF12 and BICRA) had 297 clinical features in addition to MM (Acromelic frontonasal dysostosis, Waardenburg, 298 Craniosynostosis and Coffin-Siris syndromes, respectively), that suggest MM as a 299 phenotyping expansion (Supplementary Table 1). Some subjects were lost to follow up, 300 leading to 21.6% of the phenotypes that could be excluded due to lack of full clinical 301 information. An additional 2 subjects (2.4%) shared some clinical features with OMIM 302 phenotypes but insufficient to make the clinical diagnoses. For the majority of these 82 303 subjects, the zygosity did not match the OMIM zygosity (i.e. dominant vs. recessive), so 304 it was not surprising that 70% of subjects lacked any OMIM clinical features. We 305 conclude that MM can infrequently present as partially penetrant phenotype in 306 established OMIM disorders, and suggest that specific alleles or environmental factors 307 may determine expressivity.

308

309 Discussion

310 In this study, we present the first large-scale assessment of DNMs contributing to MM

- 311 risk. Approximately 22% of MM probands had damaging DNMs, of which about 28%
- 312 were expected to contribute to MM risk. This risk is comparable to other severe pediatric

conditions that are likely under strong purifying selection, as the mutations are unlikely to
propagate to offspring⁴⁴⁻⁴⁶. In addition to the LGD DNMs found in other severe pediatric
conditions, we found strong enrichment of D-Mis DNMs, suggesting that some LGD
mutations in these genes may be lethal during embryogenesis. It would be interesting to
assess the contribution of D-Mis mutations in other severe pediatric conditions.

Although only a subset of the genes identified likely contribute risk, we found that 318 319 candidate MM genes were more interconnected than expected by chance. This lends 320 support to the existence of a 'Meningomyel-ome', characterized by numerous genes that 321 have potential to affect phenotype, interconnected by regulatory or protein-interaction 322 networks, aligning with an omnigenic model⁴⁷. Many of the networks highlight pathways 323 previously implicated from mouse or frog models, including Wnt signaling, planar cell 324 polarity, actin regulation and cell signaling. Notably, there was little overlap of mutated 325 genes in humans with animal NTD models. One difference is that mouse and frog NTD genes are often identified as lethal embryonic phenotypes^{48,49}, whereas our ascertainment 326 327 was limited to living subjects. Thus, while the genes implicated in laboratory animals vs. 328 human NTDs may be different, we expect the pathways to be highly similar, evident in 329 the Meningomyel-ome. Future work could introduce human DNMs into vertebrate 330 models or human neural tube stem cell models, to bridge this divide.

331 Of the 187 genes with DNMs in MM subjects, 83 were previously implicated in 332 human phenotypes according to OMIM. Only two of these OMIM conditions listed MM 333 as part of the associated spectrum, and in only five subjects was the overlap sufficient for 334 clinical diagnosis of the linked OMIM phenotype. This suggests that MM should be 335 considered as part of the clinical continuum of a variety of OMIM conditions, which may 336 be expressed in an allelic- or zygosity-specific fashion. Surprisingly, only five of the 187 337 genes were recurrently mutated in our cohort, suggesting there could be thousands of 338 genes contributing to MM risk (Supplementary Information).

Our findings do not resolve the pathogenesis of most MM cases. Rare and de
 novo copy-number variants⁵⁰, or inherited variants could also contribute to risk⁵¹. It is
 also possible that regulatory mutations contribute, perhaps modulated by folic acid.
 Lastly, evidence of gene dosage sensitivity raises the possibility that environmental

343 factors during critical developmental windows might amplify the effects of mutations.







46 **Figure 1. Enrichment of damaging DNMs in MM versus control. a,** DNMs

347 categorized by predicted functional impact: LGD (likely gene disrupting), D-Mis

348 (damaging missense), D-Mis-HC (damaging missense of high confidence, called from a

meta predictor), Tolerant Mis (missense of tolerant functional impact), and Synonymous.
 DNM rates per proband in MM (left sides of the triangle with strips) and control (right

DNM rates per proband in MM (left sides of the triangle with strips) and control (right
 sides). Areas represent the ratio of the DNM rates between MM and controls within each

functional category. Hashed: MM: Unhashed: controls. **b–c.** Variant rate (10^{-8}) and

353 theoretical rate (DNM rate per child) on left and right y-axis, respectively. Statistical

analysis of the ratio of DNM rates between MM (triangles) and controls (circles), denoted

by ratio of the two Poisson rates, or rate ratio (RR), calculated within (b) 'All genes' (n =

19,658) and (c) 'Constrained genes' (n = 3,060; pLI ≥ 0.9). Theoretical rate was

357 calculated by normalization of the variant rate with the total size of hg38 coding region

358 (59,281,518 bp). Observed and theoretical DNM rates are marked in the left and right y-

axis, respectively. *P* values were calculated by a one-sided rate-ratio test. *P* values:

360 *** < 0.001, ** < 0.01, * < 0.05. ns: not significant.





364 Figure 2. Functional convergence of genes implicated by damaging DNMs. a, 365 Proportion of singletons (DNM occurred in one trio) and doubletons (DNMs occurred in two independent trios) damaging (LGD or D-Mis) genes in controls (green) and MM 366 (yellow). Six doubleton genes were annotated with variant functional categories (LGD, D-367 368 Mis-HC, or D-Mis). b, A protein-protein interaction network composed of MM DNM genes. Genes connected by at least one edge are shown; unconnected (orphan) genes are 369 370 shown in Extended Data Fig. 3a. Node color: variant functional categories: LGD (purple), 371 D-Mis (light pink), and D-Mis-HC (dark pink). Doubleton genes: green borders. Edge 372 thickness: confidence score of the protein interaction, defined in the STRING database. c, 373 Distribution of the total number of edges in 100,000 networks randomly generated with 374 bootstrapping (selecting gene set size of 108 (i.e. 80% of the 135 control DNM genes) in 375 control (green) and MM (yellow). Higher number of edges denotes denser network 376 interconnection. P values calculated by two-sided Wilcoxon rank-sum test. d. Number of 377 nodes with n (0 to 10) edges in controls (green) and MM (yellow) gene sets. Error bars: 378 first and third quartile. P values calculated by a one-sided Wilcoxon rank-sum test. e, GO 379 (Gene Ontology) term network visualization for genes overlapping with 187 MM DNM 380 genes with statistical significance (a.k.a., GO enrichment analysis). GO terms of functional 381 relevance connected by an edge via commonly involved genes (small circles). Node sizes: 382 significance of the terms. Degree of connectivity between terms (edges): kappa statistics 383 by ClueGO. ****P value < 0.0001. ns: not significant.

- 384
- 385
- 386



389 Figure 3. Functional modules that contribute to MM risk. a, Functional submodules 390 clustered from the propagated network, 'Meningomyel-ome', with the 187 damaging 391 DNM genes from MM cohort used as seeds. Clustered with a Leiden algorithm with co-392 expression value from STRING database as attributes, five submodules annotated FDR < 393 10⁻⁶ by Gene Ontology (GO) Biological Process, KEGG, or Reactome databases shown. 394 **b**, Topmost significantly enriched GO Biological Processes with $FDR < 10^{-8}$ shown. FDR 395 value: -log¹⁰ scale. LGD DNMs genes: blue triangle. D-Mis DNMs: blue circles. Propagated genes: small purple circles. Functional terms annotated with $FDR < 10^{-8}$ 396 397 colored with light purple background. 398





400 Figure 4. Functional validation of damaging DNMs related to actin polymerization. a, Damaging DNM genes highlight 'GTPase involved actin cytoskeleton pathway' 401 402 mediated by WASP and WAVE, involving three GTPases (CDC42, RAC1, and RHOA) 403 and five mutated genes TNK2, TIAM1, WHAMM, PLCE1, and BRSK2. Red circle: LGD 404 DNM, Dark yellow circle: D-Mis DNM. b, TNK2 p.P168L patient mutation impaired 405 WASP phosphorylation from immunoprecipitation (IP) kinase assay, compared to WT 406 and kinase dead p.A156T. c-d, TIAM1 p.H1149P patient mutation showed fewer 407 lamellipodia (F-actin) compared to WT, (c) imaged with Phalloidin and (d) quantified. 408 Kruskal-Wallis followed by a pairwise Wilcoxon test, P value adjusted with Bonferroni. 409 Data shown with Hampel filter and images masked to remove other cells. e, TIAM1 p.H1149P patient mutation decreased Rac1 activation with constitutively active (C.A.) 410 411 Src, observed with Förster resonance energy transfer (FRET). Kruskal-Wallis followed 412 by a pairwise Wilcoxon test, P value adjusted with Bonferroni. Data shown with Hampel 413 filter. f. Dorsal views of *Xenopus laevis* embryos injected with Whamm morpholino 414 (MO) at Stage 19. Neural tube closure phenotypes observed in a dose-dependent manner 415 with 5 and 10 ng MO. g, Neural folds visualized by *pax3* in situ hybridization in the late 416 neural stage. h, Quantification of distance between neural folds. Newman-Keuls (two-417 sided) for control versus multiple conditions after ANOVA. P values: **** < 0.0001, 418 *** < 0.001, ** < 0.01, * < 0.05. ns: not significant, LGD: likely-gene disrupting, D-Mis: 419 damaging missense; WT: wild-type.

420 **References**

421		
422	1	Iskandar, B. J. & Finnell, R. H. Spina bifida. N Engl J Med 387, 444-450 (2022).
423		https://doi.org/10.1056/NEJMra2116032
424	2	Lee, S. & Gleeson, J. G. Closing in on mechanisms of open neural tube defects.
425		Trends Neurosci 43, 519-532 (2020). https://doi.org/10.1016/j.tins.2020.04.009
426	3	Prevention of neural tube defects: results of the Medical Research Council
427		vitamin study. MRC Vitamin Study Research Group. Lancet 338, 131-137 (1991).
428	4	J, A. Myelocyste, transposition von gewebskeimen und sympodie. Vol. Beitr Path
429		Anat 16:1–28, 1894 (1894).
430	5	Chiari, H. Uber veränderungen des kleinhirns infolge von hydrocephalie des
431		grosshirns. Dtsch Med Wochenschr 17, 1172–1175 (1891).
432	6	Wilde, J. J., Petersen, J. R. & Niswander, L. Genetic, epigenetic, and
433		environmental contributions to neural tube closure. Annu Rev Genet 48, 583-611
434		(2014). https://doi.org/10.1146/annurev-genet-120213-092208
435	7	Carter, C. O. & Evans, K. Spina bifida and anencephalus in greater London. J
436		Med Genet 10, 209-234 (1973). https://doi.org/10.1136/jmg.10.3.209
437	8	Zhang, T. et al. Genetic variants in the folate pathway and the risk of neural tube
438		defects: a meta-analysis of the published literature. <i>PLoS One</i> 8 , e59570 (2013).
439		https://doi.org/10.1371/journal.pone.0059570
440	9	Lei, Y. et al. Identification of novel CELSR1 mutations in spina bifida. PLoS One
441		9, e92207 (2014). https://doi.org/10.1371/journal.pone.0092207
442	10	Kibar, Z. et al. Mutations in VANGL1 associated with neural-tube defects. N
443		Engl J Med 356, 1432-1437 (2007). https://doi.org/10.1056/NEJMoa060651
444	11	Morrison, K. et al. Genetic mapping of the human homologue (T) of mouse
445		T(Brachyury) and a search for allele association between human T and spina
446		bifida. Hum Mol Genet 5, 669-674 (1996). https://doi.org/10.1093/hmg/5.5.669
447	12	Jensen, L. E., Etheredge, A. J., Brown, K. S., Mitchell, L. E. & Whitehead, A. S.
448		Maternal genotype for the monocyte chemoattractant protein 1 A(-2518)G
449		promoter polymorphism is associated with the risk of spina bifida in offspring.
450		Am J Med Genet A 140, 1114-1118 (2006). https://doi.org/10.1002/ajmg.a.31212
451	13	Iossifov, I. et al. The contribution of de novo coding mutations to autism
452		spectrum disorder. Nature 515, 216-221 (2014).
453		https://doi.org/10.1038/nature13908
454	14	Zaidi, S. et al. De novo mutations in histone-modifying genes in congenital heart
455		disease. Nature 498, 220-223 (2013). https://doi.org/10.1038/nature12141
456	15	Lemay, P. et al. Loss-of-function de novo mutations play an important role in
457		severe human neural tube defects. J Med Genet 52, 493-497 (2015).
458		https://doi.org/10.1136/jmedgenet-2015-103027
459	16	Fischbach, G. D. & Lord, C. The Simons Simplex Collection: a resource for
460		identification of autism genetic risk factors. Neuron 68, 192-195 (2010).
461		https://doi.org/10.1016/j.neuron.2010.10.006
462	17	Rahbari, R. et al. Timing, rates and spectra of human germline mutation. Nat
463		Genet 48, 126-133 (2016). https://doi.org/10.1038/ng.3469

464	18	Kessler, M. D. <i>et al.</i> De novo mutations across 1,465 diverse genomes reveal
465		mutational insights and reductions in the Amish founder population. <i>Proc Natl</i>
466	10	Acad Sci U S A 117, 2560-2569 (2020). https://doi.org/10.10/3/pnas.1902/6611/
467	19	Besenbacher, S. <i>et al.</i> Novel variation and de novo mutation rates in population-
468		wide de novo assembled Danish trios. <i>Nat Commun</i> 6 , 5969 (2015).
469		https://doi.org/10.1038/ncomms6969
470	20	Frome, E. L. The analysis of rates using Poisson regression models. <i>Biometrics</i>
471		39 , 665-674 (1983).
472	21	Willsey, A. J. et al. De novo coding variants are strongly associated with Tourette
473		Disorder. Neuron 94, 486-499 e489 (2017).
474		https://doi.org/10.1016/j.neuron.2017.04.024
475	22	Kong, A. et al. Rate of de novo mutations and the importance of father's age to
476		disease risk. Nature 488, 471-475 (2012). https://doi.org/10.1038/nature11396
477	23	Goldmann, J. M., Veltman, J. A. & Gilissen, C. De novo mutations reflect
478		development and aging of the human germline. Trends Genet 35, 828-839 (2019).
479		https://doi.org/10.1016/j.tig.2019.08.005
480	24	Turner, T. N. et al. Genomic patterns of de novo mutation in simplex Autism.
481		Cell 171, 710-722 e712 (2017). https://doi.org/10.1016/j.cell.2017.08.047
482	25	Martin, J. et al. A brief report: de novo copy number variants in children with
483		attention deficit hyperactivity disorder. Transl Psychiatry 10, 135 (2020).
484		https://doi.org/10.1038/s41398-020-0821-v
485	26	Sanders, S. J. <i>et al.</i> Multiple recurrent de novo CNVs, including duplications of
486		the 7a11.23 Williams syndrome region, are strongly associated with autism.
487		<i>Neuron</i> 70 , 863-885 (2011), https://doi.org/10.1016/i.neuron.2011.05.002
488	27	Hol. F. A. <i>et al.</i> A frameshift mutation in the gene for PAX3 in a girl with spina
489		bifida and mild signs of Waardenburg syndrome. J Med Genet 32 , 52-56 (1995).
490		https://doi.org/10.1136/img.32.1.52
491	28	Szklarczyk, D. <i>et al.</i> The STRING database in 2023: protein-protein association
492	20	networks and functional enrichment analyses for any sequenced genome of
493		interest Nucleic Acids Res 51 D638-D646 (2023)
494		https://doi.org/10.1093/nar/gkac1000
495	29	Cowen L. Ideker T. Ranhael B. L. & Sharan R. Network propagation: a
496	2)	universal amplifier of genetic associations Nat Rev Genet 18 551-562 (2017)
497		https://doi.org/10.1038/prg.2017.38
708	30	Harris M I & Juriloff D M An undate to the list of mouse mutants with neural
490	50	tube elecure defects and advances toward a complete genetic perspective of neural
4 99 500		tube closure defects and advances toward a complete genetic perspective of neural
500		https://doi.org/10.1002/bdrp.20676
502	21	Trang V A Waltman I & yon Falt N I From Louvein to Leiden
502	51	Traag, V. A., Waltman, L. & Van Eck, N. J. From Louvain to Leiden:
505		guaranteeing well-connected communities. Sci Rep 9, 5255 (2019).
304 505	22	$\frac{\text{Intps://doi.org/10.1058/841398-019-41093-Z}{\text{Dele A Eastin S Crease N D E & Crease A L D1 CTD }$
505	32	KOIO, A., ESCUIN, S., Greene, N. D. E. & Copp, A. J. Kno G I Pases in mammalian
506		spinal neural tube closure. Small GTPases 9, 283-289 (2018).
50/		https://doi.org/10.1080/21541248.2016.1235388

508 509	33	Wallingford, J. B., Niswander, L. A., Shaw, G. M. & Finnell, R. H. The continuing challenge of understanding, preventing, and treating neural tube
510		defects. Science 339, 1222002 (2013). https://doi.org/10.1126/science.1222002
511	34	Niederkofler, V., Salie, R., Sigrist, M. & Arber, S. Repulsive guidance molecule
512		(RGM) gene function is required for neural tube closure but not retinal
513		topography in the mouse visual system. J Neurosci 24, 808-818 (2004).
514		https://doi.org/10.1523/JNEUROSCI.4610-03.2004
515	35	Kee, N., Wilson, N., Key, B. & Cooper, H. M. Netrin-1 is required for efficient
516		neural tube closure. Dev Neurobiol 73, 176-187 (2013).
517		https://doi.org/10.1002/dneu.22051
518	36	Greene, N. D., Stanier, P. & Moore, G. E. The emerging role of epigenetic
519		mechanisms in the etiology of neural tube defects. <i>Enigenetics</i> 6, 875-883 (2011).
520		https://doi.org/10.4161/epi.6.7.16400
521	37	Akimova, D. <i>et al.</i> Metabolite profiling of whole murine embryos reveals
522	- /	metabolic perturbations associated with maternal valproate-induced neural tube
523		closure defects. <i>Birth Defects Res</i> 109 , 106-119 (2017).
524		https://doi.org/10.1002/bdra.23583
525	38	Copp. A. J., Stanier, P. & Greene, N. D. Neural tube defects: recent advances.
526	00	unsolved questions, and controversies. Lancet Neurol 12, 799-810 (2013).
527		https://doi.org/10.1016/S1474-4422(13)70110-8
528	39	Schaar, B. T. & McConnell, S. K. Cytoskeletal coordination during neuronal
529	0,2	migration. <i>Proc Natl Acad Sci U S A</i> 102 , 13652-13657 (2005).
530		https://doi.org/10.1073/pnas.0506008102
531	40	Dent, E. W., Gupton, S. L. & Gertler, F. B. The growth cone cytoskeleton in axon
532		outgrowth and guidance. Cold Spring Harb Perspect Biol 3 (2011).
533		https://doi.org/10.1101/cshperspect.a001800
534	41	Geelen, J. A. & Langman, J. Closure of the neural tube in the cephalic region of
535		the mouse embryo. <i>Anat Rec</i> 189, 625-640 (1977).
536		https://doi.org/10.1002/ar.1091890407
537	42	Rolo, A. <i>et al.</i> Regulation of cell protrusions by small GTPases during fusion of
538		the neural folds. <i>Elife</i> 5 , e13273 (2016), https://doi.org/10.7554/eLife.13273
539	43	Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A. & McKusick, V. A.
540		Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes
541		and genetic disorders. <i>Nucleic Acids Res</i> 33 . D514-517 (2005).
542		https://doi.org/10.1093/nar/gki033
543	44	Jin, S. C. <i>et al.</i> Contribution of rare inherited and de novo variants in 2.871
544		congenital heart disease probands. <i>Nat Genet</i> 49 , 1593-1601 (2017).
545		https://doi.org/10.1038/ng.3970
546	45	Halvorsen, M. <i>et al.</i> De novo mutations in childhood cases of sudden unexplained
547		death that disrupt intracellular Ca(2+) regulation. <i>Proc Natl Acad Sci US A</i> 118
548		(2021). https://doi.org/10.1073/pnas.2115140118
549	46	Li, W. <i>et al.</i> De novo mutations contributes approximately 7% of pathogenicity in
550		inherited eve diseases. Invest Ophthalmol Vis Sci 64, 5 (2023).
551		https://doi.org/10.1167/iovs.64.2.5

552	47	Boyle, E. A., Li, Y. I. & Pritchard, J. K. An expanded view of complex traits:
553		from polygenic to omnigenic. Cell 169, 1177-1186 (2017).
554		https://doi.org/10.1016/j.cell.2017.05.038
555	48	Lemos, M. C. et al. Genetic background influences embryonic lethality and the
556		occurrence of neural tube defects in Men1 null mice: relevance to genetic
557		modifiers. J Endocrinol 203, 133-142 (2009). https://doi.org/10.1677/JOE-09-
558		0124
559	49	Momb, J. et al. Deletion of Mthfd11 causes embryonic lethality and neural tube
560		and craniofacial defects in mice. Proc Natl Acad Sci USA 110, 549-554 (2013).
561		https://doi.org/10.1073/pnas.1211199110
562	50	Bassuk, A. G. et al. Copy number variation analysis implicates the cell polarity
563		gene glypican 5 as a human spina bifida candidate gene. Hum Mol Genet 22,
564		1097-1111 (2013). https://doi.org/10.1093/hmg/dds515
565	51	Wolujewicz, P. et al. Genome-wide investigation identifies a rare copy-number
566		variant burden associated with human spina bifida. Genet Med 23, 1211-1218
567		(2021). https://doi.org/10.1038/s41436-021-01126-9
568		

569 **Tables**

Variant type	Theoretical rate per child (±95% CI)		% of cases with DNM mediating risk (±95% CI)	% of DNM carrying MM risk (±95% CI)
	MM (n=772)	Control (n=724)	_	
Likely Gene Disrupting (LGD)	0.12 (0.09-0.14)	0.05 (0.03-0.08)	7.16% (2.96%-11.36%)	52.43% (21.67%-83.18%)
Damaging HC	0.18 (0.14-0.21)	0.09 (0.07-0.12)	9.60% (4.45%-14.75%)	46.15% (21.38-70.92)
Damaging	0.29 (0.24-0.33)	0.21 (0.17-0.25)	9.62.% (2.64%-16.59%)	28.26% (7.75-48.76)

570

571 Table 1. Contribution of DNMs to MM risk

572 The DNM theoretical rate (i.e., DNM rate per child) of MM (n = 772) and control (n =

573 724) trios are shown with the 95% confidence interval (CI) of the rate using a one-sample

574 t-test. The % of cases with DNM mediating risk were calculated by the difference

575 between the theoretical rate of the MM and the control with 95% CI using a two-sample

576 t-test (two-sided). The % of cases with DNM mediating risk was estimated by dividing

577 the difference of theoretical rate between MM and control, by the theoretical rate of MM

578 trios, with the 95% CI using two-sample t-test. The theoretical rates were calculated

579 based on consensus regions for proper comparison of DNM rates. Damaging DNM

580 includes LGD (Likely Gene Disrupting) and D-Mis DNM. Damaging-HC (high

581 confidence) includes LGD and D-Mis-HC (high confidence).

Methods 582

583

584 Establishment of Spina Bifida Sequencing Consortium (SBSC) cohort

585 Inclusion criteria

586 Strict inclusion criteria were set for subject enrollment into the Spina Bifida Sequencing 587 Consortium (SBSC). Participants must be affected by lumbosacral meningomyelocele 588 (MM) with Arnold-Chiari malformation and hydrocephalus requiring surgical 589 intervention such as ventriculoperitoneal shunt or endoscopic third ventriculostomy. We 590 excluded subjects with closed neural tube defects, not requiring surgery at birth, with 591 meningocele, or without hydrocephalus or not requiring surgery at birth. Enrollment 592 required that both biological parents were available for sampling. In the case of fetal 593 surgery to correct MM, which reduces the incidence of hydrocephalus, the requirement 594 for inclusion of hydrocephalus at the time of enrollment was lifted. Subjects with known 595 syndromes that would explain their conditions were excluded. Any families that did not 596 meet the strict inclusion criteria were excluded.

- 597

598 Recruitment

599 The SBSC used several concurrent recruitment approaches: 1] Identify recruitable MM 600 trios from local, national, and international hospitals. 2] Social media outreach through

- 601 the Spina Bifida Association (SBA) Twitter, Facebook and Instagram accounts directly to
- 602 families. 3] Recruit from spina bifida multidisciplinary clinics around the world with high
- 603 MM caseloads. 4] Leverage historic Center for Disease Control-supported neural tube
- 604 defect (NTD) cohorts. 5] Share sequencing data that have been already generated from
- 605 trios with members of the SBSC and publicly with the NIH supported dbGaP. 6] Subjects
- 606 and/or their families also contacted the SBSC independently through our postings and
- 607 advertisements on social media. The countries where the participants were recruited 608 include the United States, Mexico, Brazil, Italy, Georgia, Egypt, Canada, Venezuela,
- 609 Pakistan, Guatemala, and Nigeria. All subjects or their guardians provided written
- 610 informed consent approved by the UCSD Institutional Review Board S99075 protocol
- 611 140028, expiration date Aug 1, 2024. Recruitment processes were conducted in
- 612 accordance with the approval by review boards of the University of California San Diego,
- 613 operating under Federal-wide Assurance number, FWA00004495. The above rulings
- 614 cover all aspects of our study, not just recruitment and consent.
- 615
- 616 Identifiers
- 617 The subject IDs used in this study cannot reveal the identity of the study subjects. These
- 618 IDs are not know to anyone outside the research group.
- 619
- 620 *Study questionnaire*
- 621 All families prospectively recruited completed a standardized SBSC Questionnaire,
- which confirmed inclusion criteria, documented past medical history and current status 622
- by adopting prior questionnaire fields⁵², along with place and date of birth of affected and 623
- 624 parents to control DNM rate for parental age at the time of conception.
- 625
- 626 Subject sample and data handling

- 627 DNA was extracted from blood or saliva by standard salt extraction protocols using
- 628 Qiagen (Germantown, MD) or Autogen (Holliston, MA) proto\ prior CDC-funded
- 629 recruitment efforts where recontact was not possible, and thus they were considered 'lost
- 630 to follow-up' for sample re-collection. There were 37 families that had prior trio WES¹⁵
- 631 where data was incorporated into the cohort using the standardized bioinformatics
- 632 pipeline.
- 633

634 Sequence data generation

In total, 2541 samples from 851 MM trios (839 trios and 6 quartets) were eligible for
whole exome sequencing with six target capture kits (Roche Exome V2, Agilent xGen
Exome V1, Agilent SureSelect v4, Agilent SureSelect V4, IDT xGen Exome V2, and
Twist human comprehensive exome), each trio sequenced by using the same capture kit.
Samples with low concentration of DNA, gender discordant, or contamination yielded 45
samples to be failed quality control, resulting in 794 trios and 6 quartets. For control trios,

- we obtained 732 healthy trios from the SAFARI cohort¹⁶, 2202 WES data captured with
- 642 NimbleGen EZ v2.
- 643

644 Data preprocessing and quality control

- Raw reads were aligned to reference genome (GRCh38) using bwa mem (0.7.17),
- 646 preprocessed with PICARD (2.20.7) AddOrReplaceReadGroups and MarkDuplicates.
- 647 Germline variants were collected with GATK (v4.11.0) HaplotypeCaller in the reference
- 648 confidence model (-ERC GVCF) to be combined via CombineGVCF, generating a joint
- 649 vcf for all MM and control trios, followed by GenotypeGVCF (v4.11.0) to be jointly
- 650 genotyped. Multiallelic variants were splited (bcftools norm -m -any), Indels were
- realigned, and base quality recalibration was done with GATK (v.4.0.11) with known
- 652 Indel and population frequency information (dbSNP (146) and
- 653 Mills_and_1000G_gold_standard.indels.hg38.vcf.gz from GATK resource bundle).
- 654 Variant quality was recalibrated by GATK VQSR with HapMap
- 655 (hapmap_3.3.hg38.vcf.gz), omni (1000G_omni2.5.hg38.vcf.gz), 1000G
- 656 (1000G_phase1.snps.high_confidence.hg38.vcf.gz),
- 657 (Mills_and_1000G_gold_standard.indels.hg38.vcf.gz), and axiom
- 658 (Axiom_Exome_Plus.genotypes.all_populations.poly.hg38.vcf.gz).
- To confirm the kinship integrity within trios, we used TRUFFLE⁵³ (v1.38), removing 29
- and 7 trios from MM and control cohort, respectively. IBD1 values were extracted from
- the vcf, by only using variants with allele frequencies higher than 0.05 (--maf 0.05) to
- only use confident calls. The IBD1 for all possible sample pairs were examined and if a
- 663 parent-child IBD1 value is smaller than 0.75. Also, samples having more relations (IBD1
- ≥ 0.75) with one outside of their family were removed, possibly owing to low data
- 665 quality or contamination.
- 666

667 **De novo variant calling**

- 668 De novo SNVs and Indels were collected following GATK genotype refinement steps.
- 669 The genotypes of 777 MM and 725 control trios were gathered, and posterior
- 670 probabilities of the variants were calculated with CalculateGenotypePosteriors (v4.2.6.1).
- 671 We only selected de novo variants having genotype qualities (GQ) \ge 20, Mapping quality
- $(MQ) \ge 30$, and PASS in VQSR. Candidate DNMs that were found to have sequencing

673 depth (DP) \geq 12 in all three family members were kept to secure high-confident calls. To 674 remove candidates that deviate from theoretical heterozygous states (AF=0.5), a two-675 sided binomial test was conducted to all positions by applying read depths and number of 676 alternative alleles, removing sites with P value > 0.01. Genotypes of both parents were 677 examined and kept if genotyped as reference homozygous (GT=0/0). To enhance the 678 robustness of a high-confident set of DNMs, a series of post-filters were applied, by 679 examining regional information and raw allele counts. First, clustered DNMs were 680 filtered out when two or more DNMs of one proband were observed within 10 bp. 681 Second, DNMs that were found to exist in the same genotypes in parents either in MM or 682 control cohorts were also removed. For de novo SNVs, each DNM position was 683 examined by collecting raw reads with base quality (> 13) and mapping quality (> 0)684 criteria for each trio (bcftools mpileup v1.9). Then, to remove artifacts derived from miscellaneous alignment, a position was filtered out when a same alternative allele was 685 686 observed in either of the parents. Two-sided binomial test was once more applied for 687 SNVs with raw read counts, with a strict cutoff 0.05. All Indels were manually inspected 688 with IGV (Integrative Genomics Viewer) by three experienced experts. The schematic 689 overview of the DNM detection pipeline is shown in Extended Data Fig. 16a. VEP 690 (v106) was used to annotate de novo variants with 1000 genomes (phase 3), COSMIC 691 (92), ClinVar (202109), ESP (V2-SSA136), HGMD-PUBLIC (20204), dbSNP (154), 692 GENCODE (Human Release 40), gnomAD (r2.1.1), PolyPhen (2.2.2) and SIFT (5.2.2).

- 693 Mutational signatures were collected by Mutalisk⁵⁴ using linear regression.
- 694

695 **DNM statistical confirmation**

696 Consensus region for DNM rate calculation

697 To compare DNM rates and burden among sequencing data generated with different 698 platforms (e.g., exome capture libraries), genomic regions that are commonly covered 699 with sufficient coverage (that is, consensus region) were extracted. For each individual 700 genome coverage was calculated using bedtools⁵⁵ (v 2.30.0) genomecov. Then, the 701 coverage bedgraphs were merged into each trio using bedtools unionbedg, and only the 702 regions with read depth > 12 in all three family members were kept. Each family 703 bedgraph was merged with bedgraphs of other families within each batch, to confirm if at 704 least 70% of families covered that region. Finally, the batch bedgraphs were merged into

- a final consensus region, reaching 36,553,428 bp.
- 706

707 DNM rates examined with Poisson distribution

708 DNMs located in the consensus region were collected, to confirm if the number of DNM

- per proband follows an expected Poisson distribution. Briefly, we assumed a cutoff of
- 710 DNM count per proband from 1 to 20, generating DNM sets based on the cutoffs. Then,
- an expected Poisson distribution was generated per cutoff, with lambda as an average
- count of DNMs per proband (R dpoi). An observed distribution of DNMs per proband
- 713 was calculated to be compared to the expected distribution, with Chi-Square goodness-of-
- 714 fit test (R chisq.test). A cutoff of 7 DNMs per proband was set (Extended Data Fig. 2c-
- 715 2d), removing five and one trios from MM and controls, respectively. The six samples
- vith DNM counts larger than 7 were found to have DNMs ranging from 8 to 484,
- 717 possibly owing to low data quality.
- 718

719 **DNM burden analysis**

720 DNM rates were calculated based on the number of DNMs observed in the consensus region, to properly compare the rates. We utilized a rate ratio test given that the number 721 722 of DNMs per proband followed Poisson distribution. The DNMs were categorized into 723 likely gene disrupting (LGD) including frameshift Indels, stop gained, and splice 724 donor/acceptor mutations. Among the missense variants, if annotated as 'probably 725 damaging' or 'likely damaging' in PolyPhen or 'deleterious' in SIFT, when CADD 726 prediction score (>20) supports either at the same time, we annotated DNMs as damaging 727 missense (D-Mis). If a DNM was annotated as D (deleterious) by a highly strict meta 728 predictor MetaSVM⁵⁶, we prioritized them as D-Mis-HC. We could replicate the highly 729 consensus D-Mis mutations and their burden with two other independent missense 730 variant annotation predictors, MetaLR⁵⁶ and REVEL⁵⁷ (Supplementary Information 731 and Extended Data Fig. 16b). MetaSVM, MetalLR, and REVEL was annotated based 732 on dbNSFP (4.1a). Missense mutations that were not annotated as D-Mis were 733 categorized as 'Tolerant missense'. Constrained genes were collected with pLI ≥ 0.9 . 734 DNM rate was calculated within the consensus region (36,553,428 bp) in the mutation 735 categories, with 95% confidence intervals calculated (one sample t test). Two-sided 736 Wilcoxon rank-sum test was utilized to confirm the difference of the total DNM rates 737 between MM (n = 772) and controls (n = 724). Rate ratio test (one-sided) was used to 738 compare two Poisson distributed rates from each cohort. Theoretical DNM rates were 739 estimated based on the total size of the coding region in hg38 (59,281,518 bp). The 740 percentage of the subjects with DNM mediating risk could be calculated by the difference 741 between the theoretical rates (DNM rate per exome) of the MM and control (95% CI 742 calculated with Wilcoxon rank-sum test, two-sided). The percentage of DNM carrying 743 the MM risk was estimated by dividing the difference of theoretical rate by the theoretical 744 rate of MM trios.

745

746 Whole genome analysis

747 We additionally recruited 101 trios and 1 quartet with MM and generated whole genome 748 sequencing (WGS) data with Illumina HiSeq2500 and NovaSeq. The reads were 749 preprocessed and aligned with the same pipeline of WES data. Same quality controls with 750 WES data were applied, removing 4 trios that failed kinship integrity and contamination 751 analyses. Small SNVs and Indels were collected with the same variant calling and 752 filtering of WES analysis. We applied a binomial test to confirm if a DNM was derived 753 from a heterozygous state as in WES, with applied stronger P value cutoff 0.05 compared 754 to WES, as WGS data has much stable coverage with reduced capture bias and allelic 755 imbalance. Additional populational allele frequency information (gnomAD genome 756 v3.1.2) was added and SpliceAI (v1.3.1)⁵⁸ was utilized (score > 0.5) to predict splice

- disrupting variants. We annotated noncoding variants with GREEN-VARAN⁵⁹ (GREEN DB schema 2.5) to annotate DNMs in noncoding regions. For copy number variant
- analysis (CNV), CNVpytor (1.3.1)⁶⁰ was utilized with a window size of 100 kbp, and
- 760 manually curated by confirming the read depths of all father and mother. To
- 761 comprehensively detect structural variants (SVs), we utilized Manta⁶¹ (1.6.0), Delly⁶²
- 762 (v0.8.1), and smoove⁶³ (0.2.6) and merged the SV calls from the three callers with
- 763 Survivor (1.0.7, parameter: dist=50000, callers=0, type=0, strands=0, estimate=0,

size=50000) to confirm if the detected SVs only present in probands.

765

766 Multiplexed Error Robust In-Situ Hybridization (MERFISH)

767 MERFISH was performed as described previously at the UCSD Epigenomics Core⁶⁴. 768 Briefly, mouse embryos at day 10.5 were fixed in paraformaldehyde and cryopreserved in 769 30% sucrose, embedded in Optimal cutting temperature (OCT) and sectioned into 12 µm 770 sections in cryostat. These tissue sections then underwent fluorescent in situ hybridization 771 with a panel of oligonucleotide probes specific for 36 of the genes identified from the 772 current human DNM cohort along with 107 marker genes, chosen upon previously 773 published single cell literatures to classify cell types into 7 cell types (neuron, neural 774 progenitor, neural crest, pre-epithelial to mesenchymal transition neural crest progenitor 775 (Pre-EMT-NCP), dorsal root ganglia, blood and mesoderm⁶⁵⁻⁶⁷. During downstream 776 analysis marker genes were filtered to only include 66 the most efficient markers specific for each cell type (see Supplementary Data for a full list of utilized marker genes). 777 778 Probes were designed and manufactured with standard pipeline by Vizgen 779 (https://vizgen.com/gene-panel/). Tissue sections were prepared and processed using 780 Vizgen sample preparation protocol (Document Number 91600002 Rev A), then samples 781 placed in the Merscope for imaging and decoding (Document Number 91600001, Rev 782 G). Raw data was analyzed using Scanpy (1.9.1)⁶⁸. Cells were preprocessed and filtered 783 using the following criteria: cells with volume less than 100 μ m³, cells with volume 784 larger than 3x median volume of all cells, fewer than 4 genes detected, fewer than 10 785 transcripts detected, total RNA counts lower than the 2% quantile or higher than 98% 786 quantile. Preprocessed cells were clustered based on gene expression using the Leiden algorithm (leidenalg 0.10.2), annotated using scType⁷³ (v1.0) based upon marker genes as 787 788 the reference set (see Supplementary Information). Clusters were annotated to the cell 789 type with the highest overall score from scType, accounting for expression of all marker 790 genes per cell type in a focal cluster, compared to the expression in other clusters. 791 Clusters with prediction score less than 0 or low confidence scores (score less than 10%) 792 of the number of cells in each cluster) were classified as indeterminate as they could not 793 be classified in any of the 7 cell types. Expression of each of the 36 candidate genes was 794 then analyzed in each cell from raw data, and percentage of total average expression per 795 cell type calculated in Extended Data Fig. 5.

796

797 Network analysis (co-localization and degree)

798Relationship between damaging DNMs in MM vs. control cohorts and the human799genome network were calculated using STRING (v11.5) for gene interactions. We800calculated the connectedness from the STRING database of damaging DNMs from MM801(n = 187) and control (n = 135) among 19,699 annotated genes, randomly resampled with802a size of 80% of the gene set from control (n = 108), of 100,000 iterations. Number of803edges per iteration were compared with a Wilcoxon rank-sum test (two-sided). Edges per804nodes were compared between the cohorts (Wilcoxon rank-sum test, one-sided).

805

806 **Pathway enrichment analysis**

807 To estimate if the MM or control DNM gene sets were functionally enriched in known

- 808 biological pathways, gene ontology (GO) biological process, reactome, and KEGG
- 809 pathways, we conducted a gene enrichment analysis with ClueGO (v2.5.10) in Cytoscape

- 810 (3.10.1), with parameters set as Evidence All_without_IEA (Inferred from Electronic
- annotation), GO tree interval ranging from 3 to 8, and 5 minimum number of genes, 4%
- 812 of genes for GO term selection, and 0.4 kappa score. We used adjusted *P* value with
- 813 Bonferroni step-down with significance criterion 0.05. Detailed information of the GO
- 814 enrichment test can be found in **Extended Data Table 3**. No significant term was
- 815 observed with control gene sets.
- 816

817 Sanger confirmation

818 Out of 198 damaging DNMs, 86% (171 out of 198) where trio DNA samples were 819 available for the Sanger sequencing confirmation, with sufficient DNA. For a subset of

- 820 detected damaging DNMs, primer sets were generated via Primer3 and ordered from
- 821 IDT. The primer lengths were configured to span a range of 18 bp to 23 bp, targeting an
- ideal size of 20 bp. The GC content was set to a minimum of 30% and a maximum of
- 70%, and the annealing temperature was established to range between $57^{\circ}C$ and $62^{\circ}C$,
- 824 with an optimal temperature of 59°C. PCR was performed using the QIAGEN Taq DNA
- 825 Polymerase kit and primer concentrations of 500 nM. Four reactions were performed per
- 826 DNM, amplifying DNA from the father, mother, affected child, and an unrelated healthy
- 827 individual. PCR products were confirmed by agarose gel electrophoresis, purified by
- 828 incubation with Exonuclease I/Shrimp Alkaline Phosphatase (1:2), diluted in ddH2O, and
- 829 shipped to Genewiz/Azenta for Sanger sequencing. Trace files were analyzed in
- 830 SnapGene Viewer and compared against the UCSC Genome Browser to confirm that the
- affected child was heterozygous for the detected mutation and the father, mother, and
- control were homozygous for the reference base at the same locus.
- 833

834 Network propagation and submodule identification

A propagated network was constructed with NetColoc $(0.1.7)^{69}$. PCNet⁷⁰ was utilized for 835 836 the background human gene interaction network, which contains 18,820 nodes and 837 2,693,109 edges. Among 187 MM genes, two genes (SLCO1B3-SLC01B7 and H3-4) 838 couldn't be included as seeds because they couldn't be found in the PCNet. As 839 implemented in NetColoc, w prime and w double prime value was calculated for each 840 gene to generate z scores for proximity. We used the z score threshold 3 as default. The 841 entire list of the genes in the propagated network can be found in **Supplementary Data**. 842 Known mouse NTD genes (n = 374) were based on previous literatures, where 205 genes were organized back in 2010^{30} and the others were added from then (see Supplementary 843 844 **Data** for the gene list). To examine the propagated network, we conducted a 845 hypergeometric test, utilizing 18,820 as the total number of genes as in PCNet (M =846 18,820), number of known NTD genes (n = 374), the number of nodes in the propagated 847 network (N = 439), and the number of overlapping genes with propagated network and MM genes (k = 17).

848 849

$$Pr(X = k) = f(k; M, n, N)$$

850 Then, to identify small functional modules from the expanded network, the propagated

- network was clustered with a Leiden algorithm with 0.5 resolution, 0.01 beta with 45
- 852 iterations. To use co-expression value as attributes, we again transferred the propagated
- 853 network to STRING database (v12) with Homo Sapiens full STRING network, popping
- out 114 nodes without edges to the network, meaning discrepant sources of protein
- network. In total, 15 small clusters were generated with more than five nodes. Five could

- 856 be significantly enriched by functional biological terms (FDR $< 10^{-5}$) by the GO
- 857 biological process, KEGG pathway without disease related terms, and Reactome, which
- 858 had more than 30% of the nodes derived from damaging DNMs (Supplementary Data).
- 859 Two clusters annotated as 'GTPase involved actin cytoskeleton' and 'Microtubule-based
- 860 process' were enriched with functional terms with most significant P values (FDR $< 10^{-10}$
- 861 ⁸), with 8 and 4 terms respectively. The pLI of the genes in the five functional modules
- 862 can be found in Supplementary Data.
- 863

864 Cloning

- 865 Patient DNMs were mutagenized into wildtype (WT) cDNA using Gibson Assembly
- 866 cloning. These mutations include p.R231G (R230G in mouse) in *Vwa8b* (mouse),
- 867 p.E521Q and p.E623Q in PLCE1 (human), p.P168L in TNK2, p.H1149P TIAM1,
- 868 p.R620H in *BRSK2* (human) and p.R349C in *CLIP2* (rat). For each of the plasmids,
- 869 overlapping (40 bp) forward and reverse primers with 20 bp 5' overhangs were designed
- 870 complementary to the mutation site, with a single nucleobase difference corresponding to
- 871 the mutation of interest (Supplementary Data). 15 ng plasmid DNA was amplified using
- 872 the NEB Phusion High-Fidelity 2X Master Mix [NEB #M0531] for 25 cycles, after
- 873 which the reaction was subjected to 1 hour at 50°C with NEBuilder HiFi DNA Assembly
- 874 2X Master Mix [NEB #E2621], and the reaction mixture was treated with DpnI [NEB 875
- #R0176] digestion for 37°C for 30 minutes. 2 µL of the reaction mixture was then 876 transformed into NEB DH5-alpha Competent E. coli [NEB #C2987], with successful
- 877 mutation verified using Primordium whole plasmid sequencing.
- 878

879 **Protein analysis**

880 TNK2

- 881 *Cell transfection. lysis. and Western blotting*
- 882 Human embryonic kidney (HEK)293T cells (from American Type Culture Collection) 883 were maintained in DMEM (Corning) supplemented with 10% fetal bovine serum 884 (Sigma) and 1X penicillin and streptomycin. The cells were transfected according to the 885 protocol supplied with TransIT reagent (Mirus) using 7.5 µg of DNA. After 48 hours, the 886 cells were harvested, washed with phosphate-buffered saline, and lysed in a buffer
- 887 containing 25 mm Tris-HCl (pH 7.5), 100 mm NaCl, 1 mm EDTA, 1% Nonidet P-40, 5
- 888 µg/ml leupeptin, 5 µg/ml aprotinin, 1mM PMSF, and 200 µM Na3VO4. Cell lysis
- 889 proceeded for 30 minutes at 4°C with rocking. The cell suspensions were centrifuged at
- 890 15,000 rpm for 10 minutes, and protein concentrations of the soluble lysates were 891
- measured using a colorimetric Bradford assay. The lysates (100 μ g) were analyzed by 892 SDS-PAGE and Western blotting using the following antibodies: phospho-Ack1/Tnk2
- 893 (Millipore Sigma 09-142), Flag (Sigma-Aldrich A8592), and gamma-tubulin (Sigma-
- Aldrich T6557).
- 894
- 895

896 Immunoprecipitation (IP) Kinase assay

- 897 IP-kinase assays were performed essentially as described with the following
- 898 modifications: HEK293T lysates (1 mg) were incubated with 40 μ L of anti-Flag M2
- 899 affinity resin (Sigma) on a rotator at 4 °C overnight, then washed three times with Tris-
- 900 buffered saline (TBS). The IPs were divided into three portions. One portion of each
- 901 sample was mixed with a gel-loading buffer, boiled for 3 minutes, and analyzed by 7.5%

902 SDS/PAGE with anti-Flag Western blotting. The remaining two samples were used for

903 duplicate activity measurements using the phosphocellulose paper-binding assay. The

reactions contained 20 mm Tris-HCl (pH 7.4), 10 mm MgCl2, 0.25 mm ATP, 1 mM

905 WASP peptide (KVIYDFIEKKG) and 20–50 cpm/pmol of $[\gamma$ -32P] ATP. Reactions were

906 carried out at 30 °C for 15 min. Incorporation of 32P into peptide was measured by 907 scintillation counting.

907 scintillation counting.908

909 **TIAM1**

910 DNA Reagents

The following constructs were previously described: pCMV-EGFP⁷¹, pCMV-Flag-Tiam1
(WT-Tiam1)⁷², pRaichu-RaichuEV-Rac1 (2248X)⁷³, pcDNA3.1 vector⁷⁴. mRuby3 was
obtained from Addgene (127808).

- 914
- 915 *Cell culture and transfections*

916 Cos-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Corning 10-917 013-CV) supplemented with 100 U/ml penicillin/streptomycin (Invitrogen 15140122) and 918 10% heat inactivated fetal bovine serum (Atlanta Biologicals S11150H) on cell culture-919 treated plastic (VWR 10062-880) maintained at 5% CO2, 37°C. Cells were passaged with 920 trypsin (Invitrogen 25200072) once per week. For experiments, 24 hrs prior to transfection 921 cells were plated on either nitric acid washed glass cover slips (Bellco Glass 1943-10012A) 922 or glass bottom plates (Cellvis P241.5HN) coated with 20 ug/ml Poly-D-Lysine (Corning 923 354210). Cells were transfected using Jetprime reagent (Polyplus 101000046) according 924 to the manufacturer recommendations. Twenty-four hours after transfections cells were changed to serum-free DMEM. For live cell experiments, phenol-red free DMEM (Corning

- changed to serum-free DMEM. For live cell experiments, phenol-red free DMEM (Cor
 17-205-CV) was used. Experiments were conducted 48 hours after transfection.
- 920 927
- 928 Immunocytochemistry, microscopy, and analysis
- 929 Cells were fixed with 4% Paraformaldehyde (Fisher Scientific AC169650010), 4%

930 Sucrose (Sigma S0389) in phosphate buffered saline (PBS). To confirm construct

931 expression, following fixation all cells were immunostained overnight at 4°C with anti-

- 932 Flag (Cell Signaling 14793S) primary antibody diluted in 0.3% Triton X-100, 5% goat
- 933 serum in PBS. After, cells were incubated with Cy5 anti-Rabbit secondary antibody

934 (Jackson ImmunoResearch 111-175-003) for 2 hrs at room temperature. For filamentous

935 actin experiments, cells were also incubated with Texas Red-Phalloidin (Invitrogen

- 936 T7471) during this time. Post-fixation and staining, cells grown in glass coverslips were
- mounted using the aqueous mounting solution FluorSave (EMD Millipore 345789).
- 938
- 939 Imaging

940 Filamentous actin was labeled with Texas Red phalloidin, then imaged using a Zeiss 941 AxioObserver.Z1 microscope with a 20x objective. Rac1 activation was measure in cells 942 transfected with the RaichuEV-Rac1 probe, imaged on a Zeiss LSM 880 confocal 943 microscope at 20x. Live imaging experiments were conducted at 37°C/5% CO2. Single 944 plane images were acquired with Förster resonance energy transfer (FRET) (excitation 458 945 nm, emission 522–569 nm), CFP (Donor) (excitation 458 nm, emission 463–507 nm), and 946 YFP (Acceptor) (excitation 514 nm, emission 522-569 nm), presented as normalized 947 FRET/Donor values using ImageJ (NIH). Only cells expressing constructs were selected

for analysis. GFP or mRuby3 fill visualized cell morphology via ROI cell trace, measured
for mean intensity, corrected for background, and normalized to respective controls.
Experiments were conducted with experimenters blinded to conditions. Representative
images were masked using ImageJ (NIH).

952 953 *VWA8*

954 Plasmid transfection in HEK293T cells was performed using the ThermoFisher 955 Lipofectamine 2000 transfection reagent. HEK293T cells seeded on a 6 well plate and 956 transfected with 4ug of plasmid. Cells were lysed using Modified RIPA buffer 72 days 957 post-transfection, and the lysate was spun down at 10,000g in a microcentrifuge and 958 supernatant was harvested. Empty vector, WT, and R230G protein was then quantified 959 using the Pierce BCA Assay kit (Thermo Scientific #23225), and 10 µg protein lysate was diluted in 4X SDS-PAGE Loading Buffer supplemented with 10% β-960 961 mercaptoethanol (Sigma #M3148) and loaded into each well of an Any kDa Bio-Rad 962 Mini-PROTEAN TGX [4569031] gel, and run for 30 minutes at 150 V. Proteins were 963 then transferred onto a nitrocellulose membrane [Sigma #IPVH00010] and blocked with 5% BSA (Sigma #A9418) in TBST (blocking buffer) for 1 hour at room temperature. The 964 965 membrane was then blotted with 1:1000 Anti-HA (#sc-805) and 1:5000 Anti-alpha-966 tubulin (Sigma #T6074) primary antibody in blocking buffer overnight at 4°C under 967 constant rocking. The following day the membrane was washed 4 times in TBST for 10 968 minutes, followed by 1 hour incubation in a 1:10000 anti-mouse (#715-035-150) and anti-969 rabbit (#711-036-152) HRP-conjugated secondary antibody in blocking buffer at room 970 temperature. The membrane was then washed again for 4 times in TBST for 10 minutes, 971 after which the membrane was treated with Pierce ECLWestern solution for HRP 972 detection (Thermo Scientific #32106) for 5 minutes at room temperature. The membrane 973 was then transferred into a clear plastic cover and imaged using a chemiluminescence 974 detector (Biotechnique #92-14860). Quantification of protein band intensity was 975 accomplished using the ImageJ band densitometry plugin, and final plots were created 976 using Prism.

- 977
- 978 *CLIP2*
- 979 Western blot

980 HEK293T cells were transfected with pEGFP-CLIP2 WT, R349C (TGC or TGT) either

981 with constitutively active AKT pE17K (Addgene #73050) or empty vector using

982 Lipofectamine as previously described, lysed into sample buffer, and analyzed by

- 983 western using anti-GFP antibody (1:200 Thermo Scientific #GF28R).
- 984
- 985 *Microtubule analysis*

HuH7 cells cultured in DMEM with 10% fetal calf serum (Sigma) and 1% antibioticantifungal mixture (Gibco) were transfected with pEGFP-CLIP2 WT, R349C or S352A

988 (Turbofect, ThermoFisher Scientific #R0531). Time-lapse sequences ($\Delta t = 2.4$ s, 80 frames)

989 of the CLIP2 fluorescence signal were captured using a Leica DMLB microscope through

a 100x 1.3 NA objective and a Scion CFW1312M camera. The parameters of microtubule

dynamics were computed as previously described⁷⁵. Statistical comparisons were
 performed using one-factor ANOVA.

993 **PLCE1**

994 *Cell transfection and lysis*

995 Plasmid expressing PLCE1 including the WT, p.E521Q, and p.E623Q mutations were

transfected into HEK293 cells and were maintained in DMEM supplemented with 10%

997 FBS and 1% penicillin/streptomycin. Plasmids were transfected into HEK293 cells using

- Lipofectamine (Invitrogen), grown for 48 hr and lysed in lysis buffer (1% Triton X-100,
- 50 mM Tris pH 7.4, 10 mM MgCl₂, 500 NaCl) with added protease inhibitors (Roche).
 The lysates were spun down at 20000 g/4°C/15 min and the supernatants were used for
- 1001 overnight incubation with 20 μ l of GST beads containing GST recombinant proteins on
- 1002 the rotator. After the incubation samples were washed with 800 μ l lysis buffer, the GST
- 1003 beads were collected at 500 g/4°C/2 min, the supernatants were aspirated out and this
- washing was repeated 3 times. Proteins were eluted with 20 μ l of 2x Laemmli buffer.
- 1005
- 1006 Pulldown assay
- 1007 Eluted proteins were diluted in 4X SDS-PAGE Loading Buffer supplemented with 10%
- 1008 β-mercaptoethanol (Sigma #M3148) and loaded into each well of an Any kDa Bio-Rad
- 1009 Mini-PROTEAN TGX gel, and run for 30 minutes at 150 V, samples transferred to
- 1010 PVDF membrane (Sigma #IPVH00010), blocked with 5% BSA (Sigma #A9418) in
- 1011 TBST for 1h at RT, membrane blotted with 1:1000 anti-RAC1, 1:1000 anti-CDC42,
- 1012 1:1000 anti-RHOA, and 1:1000 anti-Myc, washed in TBST for 10min then blotted with
- 1013 1:10000 anti-mouse (#715-035-150) and anti-rabbit (#711-036-152) HRP-conjugated
- 1014 antibody, washed in TBST for 10m, then developed in Pierce ECL Western solution
- 1015 (Thermo Scientific #32106) for 5min, and imaged using a chemiluminescence detector
- 1016 [Biotechnique #92-14860], and band intensity quantified using ImageJ band
- 1017 densitometry, and plotted using Prism.
- 1018

The GST-PAK1 beads (#PAK02-A) and GST-rhotekin RBD beads (#RT02-A) were
purchased from Cytoskeleton. Anti-Myc (#2278; Cell Signaling Tech.), anti-RhoA
(#2117; Cell Signaling Tech.), anti-Rac1 (#610650; BD Transduction Labs), anti-Cdc42
(#610928; BD Transduction Labs) were purchased from the indicated commercial
sources.

1024

1025 BRSK2 Western Blot

1026 HEK293T cells were transfected with the pEXP-CMV-BRSK2-Flag plasmid containing 1027 wildtype, K48A kinase-dead mutant, and R620H patient mutation BRSK2 sequence 1028 using PEI (Sigma Millipore #919012) and OptiMEM (Gibco #31985-070) according to 1029 the manufacturer's guidelines. Protein concentration of lysates was measured using the 1030 Pierce BCA Protein Assay Kit (Thermo Scientific #23225), then 20 µg of protein was 1031 loaded into each well of a 4-12% Bis-Tris Gel (Invitrogen #NP0336), transferred to 1032 nitrocellulose membranes (Thermo, #88018), blocked then blotted with one of the 1033 following primary antibodies: 1:1000 Flag rabbit (Cell Signaling Technology #14793S), 1034 1:1000 Beta-actin rabbit (Sigma #A5316), 1:1000 anti-Phospho-AMPK Substrate Motif 1035 rabbit (Cell Signaling Technology #5759) and 1:1000 mTOR rabbit (Cell Signaling 1036 Technology #2983), 1:1000 P-mTOR Ser 2448 rabbit (Cell Signaling Technology 1037 #5536), 1:1000 p70 S6 Kinase rabbit (Cell Signaling Technology #34475), 1:1000 1038 Phospho-p70 S6 Kinase Thr 389 rabbit (Cell Signaling Technology #9234), 1:1000 4E-1039 BP1 rabbit (Cell Signaling Technology #9644) and 1:1000 Phospho-4E-BP1 Thr 37/46

1040 rabbit (Cell Signaling Technology #2855) at 4°C overnight, rinsed in TBST for 10

- 1041 minutes, incubated with LI-COR IRDye 680 Donkey anti-Mouse or 800 Donkey anti-
- 1042 Rabbit (LI-COR #926-68072, #926-32213) 1:10,000 rinsed in TBST and imaged on an
- 1043 Odyssey CLx using Image Studio software for analysis of band intensity.
- 1044

1045 Xenopus modeling

- 1046 *Xenopus* embryo manipulations were conducted according to established protocols⁷⁶.
- 1047 Female adult *Xenopus laevis* were induced to ovulate by the injection of human chorionic
- 1048 gonadotropin, and *in vitro* fertilization was performed by homogenizing a small piece of
- 1049 a testis. Embryos were dejellied in 1/3 X Marc's Modified Ringer's (MMR) with 2.5%
- 1050 (w/v) cysteine (pH7.9) at the 2-cell stage and were microinjected with either gene-
- 1051 specific MO or mock into two dorsal blastomeres at the 4-cell stage in 2% Ficoll (w/v) in
- 1052 1/3 X MMR. Injected embryos were incubated at 18°C until stage 19 and fixed with 1X
- 1053 MEMFA (0.1 M MOPS, 2mM EGTA, 1 mM MgSO₄, 3.7% formaldehyde, pH 7.4). The
- 1054 gene sequence for *Xenopus* Whamm was obtained from Xenbase
- 1055 (<u>http://www.xenbase.org</u>). A Morpholino antisense oligonucleotide (MO) against
- 1056 Whamm was designed to block mRNA splicing (Gene Tools) 5' -
- 1057 AAAAGTAGGAAGAAGCCCCCACCCT -3'. The Whamm open reading frame was
- 1058 amplified from Xenopus cDNA and cloned into the pCS10R MCC vector containing GFP
- 1059 tag. Capped mRNA was synthesized using the mMESSAGE mMACHINE SP6
- 1060 transcription kit (Invitrogen Ambion, cat# AM1340), and injected to assess rescue. To
- 1061 measure the distance of the neural folds, *in situ* hybridization against Pax3 was performed
- as previously described⁷⁶. Images were captured using a ZEISS Axio Zoom V16
- 1063 stereomicroscope and associated Zen software, and neural folds visualized by pax3 were
- analyzed in Fiji. To verify the efficiency of MO, MO was injected into all cells at the 4-
- 1065 cell stage, and total RNAs were extracted from four embryos using the TRIZOL reagent
- 1066 (Invitrogen, cat # 15596026). cDNAs were synthesized using M-MLV reverse
- 1067 Transcriptase (Invitrogen, cat#28025013) and random primers (NEB, cat#S1330S).
- 1068 cDNAs were amplified by Taq polymerase (NEB, cat# M02735) using the following
- 1069 primers: 5'-CGGTGCAGGACTTGGATTAT-3', 5'-
- 1070 CCCATTTAGCTACCTCCTTCTG-3'.
- 1071

Data Availability 1072

- 1073 Exome and genome sequencing data are available in publicly accessible databases for the
- 1074 1,576 subjects enrolled after inclusion of dbGaP language into the consenting process/
- 1075 became standard. These data are at dbGaP (accession #phs002591.v1.p1,
- 1076 phs000744.v5.p2 (Yale Mendelian Sequencing Center), Kids First: Whole Genome
- 1077 Sequencing in Structural Defects of the Neural Tube Accession (phs002591.v1.p1).
- 1078 Sequencing data on the remaining 743 subjects is available upon request.
- 1079

Code Availability 1080

- 1081 Computational codes used in this study are available in GitHub
- 1082 (https://github.com/Gleeson-Lab/Publications/tree/main/MM DNM).
- 1083

Acknowledgement 1084

1085 We especially thank the families and the individuals with meningomyelocele that 1086 participated in this study, Kiely James, Renee George, Brett Copelande, Valentina

- 1087 Stanley, Celine Shen, and Jennifer Venneri from the Spina Bifida Sequencing
- 1088 Consortium, the Spina Bifida Association, the UCSD Laboratory for Pediatric Brain
- 1089 Disease for clinical and technical support, Brin Rosenthal and Katie Fisch from the
- 1090 UCSD Altman Clinical and Translational Research Institute for statistical modeling,
- 1091 Broad Institute, Yale Genetic Center, Regeneron Genetics Center, UCSD Institute for
- 1092 Genomic Medicine, UC Irvine Sequencing Center and Rady Children Institute for
- 1093 Genomics Medicine for sequencing support, Barbara Craddock from Stony Brook
- 1094 University for functional analysis of TNK2, and the Spina Bifida Association for recruitment efforts.
- 1095
- 1096

1097 Funding

- 1098 This work was supported by the Center for Inherited Disease Research grant
- 1099 HHSN268201700006I, the Yale Center for Genomic Analysis, the Broad Institute, the
- 1100 UC Irvine Genomics Core, the UCSD Institute for Genomic Medicine, the UCSD
- Imaging Core, X01HD100698, X01HD110998, HD114132, P01HD104436, 1101
- 1102 U54OD030187, and support from the Howard Hughes Medical Institute and Rady's
- 1103 Children Institute for Genomic Medicine to JGG. YJH and SK were supported by the
- 1104 National Research Foundation of Korea funded by the Ministry of Science and ICT
- 1105 (MSIT) (RS-2023-00277314). WTM was supported by VA Merit Award # I01
- 1106 BX006248.
- 1107

1108 Spina Bifida Sequencing Consortium members

1109 Dr. Allison Elizabeth Ashley Koch, PhD (Duke University), Dr. Kit Sing Au, PhD and

- 1110 Dr. Hope Northrup, MD (University of Texas, Houston), Dr. Gyang Markus Bot, MD
- 1111 (Jos University Teaching Hospital, Jos, Nigeria), Valeria Capra, MD (IRCCS Istituto
- 1112 Giannina Gaslini, Italy), Dr. Richard H. Finnell, PhD, DABMGG (Baylor College of
- 1113 Medicine), Dr. Zoha Kibar, PhD (Université de Montréal, Canada), Dr. Philip J. Lupo,
- 1114 PhD, MPH (Baylor College of Medicine), Dr. Helio R. Machado, MD (University of Sao
- 1115 Paulo, Brazil), Dr. Tony Magana, MD (Mekelle University, Mekelle, Ethiopia), Dr. Rony
- 1116 Marwan, MD (University of Colorado), Dr. Gia Melikishvili, MD (MediClub Georgia,

- 1117 T'bilisi, Georgia), Dr. Osvaldo M. Mutchinick, MD, PhD (Salvador Zubirán National
- 1118 Institute of Health Sciences and Nutrition, Mexico City, Mexico), Dr. Roger E.
- 1119 Stevenson, MD (Greenwood Genetic Center), Dr. Anna Yurrita, MD (Francisco
- 1120 Marroquín University, Guatemala City, Guatemala), Dr. Maha S. Zaki, MD, PhD
- 1121 (National Research Center, Cairo, Egypt), Dr. Sara Mumtaz, PhD (National University of
- 1122 Medical Sciences, Rawalpindi, Pakistan), Dr. José Ramón Medina-Bereciartu, MD
- 1123 (Venezuela Association of Spina Bifida, Caracas, Venezuela), Dr. Friedhelm Hildebrandt
- 1124 (Boston Children's Hospital, Harvard Medical School), Dr. Caroline M. Kolvenbach, MD
- 1125 (Boston Children's Hospital, Harvard Medical School), Shirlee Shril, MS (Boston
- 1126 Children's Hospital, Harvard Medical School), Dr. Mahmoud M. Noureldeen, MD and
- Dr. Aida MS. Salem, MD (Beni-Suef University, Beni-Suef, Egypt), Dr. Joseph Gleeson,
 MD (UC San Diego).
- 1129

1130 Author Contributions

Y-JH, CW, NM FJ, KIV, CB, SL, NJ, AP recruited subjects and performed genetic
analysis. IJ performed MERFISH analysis, CJL and JBW generated Xenopus data. AN,
J-EL, IT, FAB, KFT, SY, HJ, BB WTM, CH, SAM, HYG, BB, CP performed functional

- analysis, ZK GMB, HN, KSU, MS, AA-K, RHF, JL, HM, CA, HRM, RES, AY, SM,
- 1135 OMM, JRM-B, FH, GM, RM, VC, MMN, AMSS, MYI, MSZ recruited families. AA,
- ARS, SWK, performed sequencing. Y-JH, SK and JGG performed analysis, wrote drafts,and incorporated feedback from coauthors.
- 1138

1139 Competing interests

AA and ARS are full time employees of Regeneron Genetics Center. SK is cofounder of
 AIMA Inc., which seeks to develop techniques for early cancer diagnosis based on
 circulating tumor DNA.

1143

1144 Additional Information

- Supplementary Information is available, containing Supplementary Table andSupplementary Notes.
- 1147

1148 Method references

- 1149
- 115052Rendeli, C. *et al.* Assessment of health status in children with spina bifida. Spinal1151Cord 43, 230-235 (2005). https://doi.org/10.1038/sj.sc.3101707
- 1152 53 Dimitromanolakis, A., Paterson, A. D. & Sun, L. Fast and accurate shared
 1153 segment detection and relatedness estimation in un-phased genetic data via
 1154 TRUFFLE. *Am J Hum Genet* 105, 78-88 (2019).
 1155 https://doi.org/10.1016/j.aihg.2019.05.007
- 1156 54 Lee, J. *et al.* Mutalisk: a web-based somatic MUTation AnaLyIS toolKit for
 1157 genomic, transcriptional and epigenomic signatures. *Nucleic Acids Res* 46, W1021158 W108 (2018). https://doi.org/10.1093/nar/gky406
- 115955Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing1160genomic features. *Bioinformatics* 26, 841-842 (2010).
- 1161 https://doi.org/10.1093/bioinformatics/btq033

1162	56	Dong, C. et al. Comparison and integration of deleteriousness prediction methods
1163		for nonsynonymous SNVs in whole exome sequencing studies. <i>Hum Mol Genet</i>
1164		24, 2125-2137 (2015). https://doi.org/10.1093/hmg/ddu733
1165	57	Ioannidis, N. M. et al. REVEL: An ensemble method for predicting the
1166		pathogenicity of rare missense variants. Am J Hum Genet 99 , 877-885 (2016).
1167		https://doi.org/10.1016/i.aihg.2016.08.016
1168	58	Jaganathan, K. <i>et al.</i> Predicting splicing from primary sequence with deep
1169		learning. Cell 176 , 535-548 e524 (2019).
1170		https://doi.org/10.1016/i.cell.2018.12.015
1171	59	Giacopuzzi, E., Popitsch, N. & Taylor, J. C. GREEN-DB: a framework for the
1172		annotation and prioritization of non-coding regulatory variants from whole-
1173		genome sequencing data. Nucleic Acids Res 50, 2522-2535 (2022).
1174		https://doi.org/10.1093/nar/gkac130
1175	60	Suvakov, M., Panda, A., Diesh, C., Holmes, I. & Abyzov, A. CNVpytor: a tool
1176		for copy number variation detection and analysis from read depth and allele
1177		imbalance in whole-genome sequencing. Gigascience 10 (2021).
1178		https://doi.org/10.1093/gigascience/giab074
1179	61	Chen, X. et al. Manta: rapid detection of structural variants and indels for
1180		germline and cancer sequencing applications. <i>Bioinformatics</i> 32 , 1220-1222
1181		(2016). https://doi.org/10.1093/bioinformatics/btv710
1182	62	Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end
1183		and split-read analysis. Bioinformatics 28, i333-i339 (2012).
1184		https://doi.org/10.1093/bioinformatics/bts378
1185	63	https://github.com/brentp/smoove.
1186	64	Chen, K. H., Boettiger, A. N., Moffitt, J. R., Wang, S. & Zhuang, X. RNA
1187		imaging. Spatially resolved, highly multiplexed RNA profiling in single cells.
1188		Science 348, aaa6090 (2015). https://doi.org/10.1126/science.aaa6090
1189	65	Delile, J. et al. Single cell transcriptomics reveals spatial and temporal dynamics
1190		of gene expression in the developing mouse spinal cord. Development 146 (2019).
1191		https://doi.org/10.1242/dev.173807
1192	66	Soldatov, R. et al. Spatiotemporal structure of cell fate decisions in murine neural
1193		crest. Science 364 (2019). https://doi.org/10.1126/science.aas9536
1194	67	Simoes-Costa, M. & Bronner, M. E. Establishing neural crest identity: a gene
1195		regulatory recipe. Development 142, 242-257 (2015).
1196		https://doi.org/10.1242/dev.105445
1197	68	Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene
1198		expression data analysis. Genome Biol 19, 15 (2018).
1199		https://doi.org/10.1186/s13059-017-1382-0
1200	69	Rosenthal, S. B. et al. Mapping the common gene networks that underlie related
1201		diseases. Nat Protoc 18, 1745-1759 (2023). https://doi.org/10.1038/s41596-022-
1202		00797-1
1203	70	Huang, J. K. et al. Systematic evaluation of molecular networks for discovery of
1204		disease genes. Cell Syst 6, 484-495 e485 (2018).
1205		https://doi.org/10.1016/j.cels.2018.03.001

1206	71	Duman, R. S., Sanacora, G. & Krystal, J. H. Altered connectivity in depression:
1207		Neuron 102 75-90 (2019) https://doi.org/10.1016/j.neuron.2019.03.013
1200	72	Tolias K F <i>et al</i> The Rac1-GEF Tiam1 couples the NMDA receptor to the
1210	12	activity-dependent development of dendritic arbors and spines <i>Neuron</i> 45 525-
1210		538 (2005) https://doi.org/10.1016/j.neuron.2005.01.024
1211	73	Komatsu N <i>et al</i> Development of an optimized backbone of FRET biosensors
1212	15	for kinases and GTPases. <i>Mol Biol Cell</i> 22 , 4647-4656 (2011).
1214		https://doi.org/10.1091/mbc.E11-01-0072
1215	74	Duman, J. G. <i>et al.</i> The adhesion-GPCR BAI1 shapes dendritic arbors via Bcr-
1216		mediated RhoA activation causing late growth arrest. <i>Elife</i> 8 (2019).
1217		https://doi.org/10.7554/eLife.47566
1218	75	Henrie, H. <i>et al.</i> Stress-induced phosphorylation of CLIP-170 by JNK promotes
1219		microtubule rescue. J Cell Biol 219 (2020). https://doi.org/10.1083/jcb.201909093
1220	76	Sive, H., Grainger, Robert M, and Harland, Richard M. Early development of
1221		Xenopus Laevis: a laboratory manual., (2000).
1222	77	Samocha, K. E. et al. A framework for the interpretation of de novo mutation in
1223		human disease. Nat Genet 46, 944-950 (2014). https://doi.org/10.1038/ng.3050
1224	78	Misra, S. N. & Kearney, J. A. Alphabet Soup: Recurrent de novo mutations in
1225		novel genes causing developmental and epileptic Ecephalopathies. Epilepsy Curr
1226		18, 125-127 (2018). https://doi.org/10.5698/1535-7597.18.2.125
1227	79	Homsy, J. et al. De novo mutations in congenital heart disease with
1228		neurodevelopmental and other congenital anomalies. Science 350, 1262-1266
1229		(2015). <u>https://doi.org/10.1126/science.aac9396</u>
1230	80	Ianevski, A., Giri, A. K. & Aittokallio, T. Fully-automated and ultra-fast cell-type
1231		identification using specific marker combinations from single-cell transcriptomic
1232		data. Nat Commun 13, 1246 (2022). https://doi.org/10.1038/s41467-022-28803-w
1233	81	Ten Klooster, J. P. <i>et al.</i> Interaction between Tiam1 and the Arp2/3 complex links
1234		activation of Rac to actin polymerization. <i>Biochem J</i> 397 , 39-45 (2006).
1235		https://doi.org/10.1042/BJ20051957
1236	82	Yoo, S., Kim, Y., Lee, H., Park, S. & Park, S. A gene trap knockout of the Tiam-1
1237		protein results in malformation of the early embryonic brain. <i>Mol Cells</i> 34 , 103-
1238	~ ^	108 (2012). <u>https://doi.org/10.1007/s10059-012-0119-x</u>
1239	83	Zhao, L. <i>et al.</i> Bhlhe40/Sirt1 axis-regulated mitophagy is implicated in all-trans
1240		retinoic acid-induced spina bifida aperta. Front Cell Dev Biol 9, 644346 (2021).
1241		https://doi.org/10.3389/tcell.2021.644346
1242		

1243 Extended Data Figure

1244



1245

1246 Extended Data Figure 1. Power calculation of estimating a cohort size for DNM

detection. Power calculation showing potential number of discovered genes compared
with cohort size (350 trios), for two different v values (enrichment ratio of loss of
function variants in case versus control) and two different k values (assumed number of
risk genes). For instance, if there are 50 genes to discover (k=50), a cohort of 400 trios

1251 will identify 16 genes if LOF variants are 2.5x more common in affected (v=2.5). All

1252 calculations manage a conservative false discovery rate (FDR). Gray dash: FDR.

1253



1255 1256 Extended Data Figure 2. Quantitative and qualitative features of de novo variants.

1257 **a-b**, Mutational signatures of DNMs showing known de novo signatures 1 and 5, in both 1258 (a) MM and (b) control cohorts. 1,251 and 1,035 SNVs were utilized for the signature 1259 analysis. c-d, DNM counts per proband following Poisson distribution, examined based 1260 on cutoffs (DNM count per proband) ranging from 1 to 20. (c) Chi-Square goodness-offit (two sided) was performed with an expected Poisson distribution with (d) lambda as 1261 1262 an average DNM count per proband, for all cutoffs (see Methods). e, DNM rates for all, 1263 coding, and noncoding regions. Observed and theoretical DNM rates are marked in the 1264 left and right y-axis, respectively. Theoretical rate calculated by normalization of the variant rate with the total size of hg38 coding region (59,281,518 bp). P values were 1265 1266 calculated by a two-sided Wilcoxon rank-sum test. ns: not significant.





Extended Data Figure 3. Quantitative and qualitative features of de novo variants. **a**, Age of conception of father and mother in MM (n = 79) and control (n = 683) trios. 1270 1271 The ages of conception were compared with Wilcoxon rank-sum test (two sided). The age of conceptions were significantly higher in controls than MM, for both of the parents. 1272 P values: **** < 0.0001. b, De novo large CNVs (> 100kb) detected from WGS. Read 1273 1274 depths of proband, father, and mother shown. Gray lines: read depths. Green lines: copy 1275 number. 1276











1283 Extended Data Figure 4. Spatial expression of DNM genes with MERFISH. Spatial

- 1284 expression of the 36 MM genes with damaging DNMs. **a**, Gene expression of marker
- 1285 genes for seven selected cell types (neuron, neural progenitor, pre-epithelial to
- 1286 mesenchymal transition neural Crest progenitor (NC progenitor), neural crest, mesoderm,
- 1287 dorsal root ganglia, and blood), in seven embryonic replicates (regions) 1 (top)-7
- 1288 (bottom). **b**, Spatial expression pattern of 36 damaging DNM genes. The seven replicates
- 1289 (X axes) of mouse E10.5 showing the gene expression pattern of candidate genes (Y
- 1290 axes). R=Rostral, C=Caudal, V=Ventral, D=Dorsal.



1292 Extended Data Figure 5. Cell type expression of the DNM genes in MERFISH. a,

1293 Expression of the 36 damaging DNMs in seven cell types: neuron, neural progenitor, pre-

epithelial to mesenchymal transition neural crest progenitor (Pre-EMT-NCP), neural

1295 crest, mesoderm, dorsal root ganglia, and blood. Indeterminate refers to the cells that

1296 were not specified with the marker genes designed for the seven cell types. **b**, Expression

1297 of marker genes used for specifying the cell types in MERFISH. Marker genes are shown

1298 within the cell type category which they represent.



1299 1300

1301 Extended Data Figure 6. Connections of genes having damaging DNMs of MM and

1302 control cohorts. a-b, Genes with damaging DNMs (LGD + D-Mis) and their

interconnections based on the STRING database, are shown for (a) MM and (b) control
 cohorts. Node color: variant functional categories: LGD (purple), D-Mis (light pink), and

- 1305 D-Mis-HC (dark pink). Doubleton genes: black borders. Edge thickness: confidence
- 1306 score of the protein interaction.



1307

1308 Extended Data Figure 7. A human 'Meningomyel-ome' constructed with damaging

1309 **DNMs contributing to MM risk.** By using the 187 damaging MM DNM genes, a

1310 propagated network, Meningomyel-ome, was generated with NetColoc⁶⁹ with a

1311 background protein network PCNet⁷⁰, incorporating 439 nodes and 2,447 edges. Big blue

1312 circle: damaging DNM genes, Small purple circle: propagated gene, Green border:

- 1313 known mouse NTD genes. The network is visualized with Cytoscape with STRING
- 1314 database.



1315DNMPropagated1316Extended Data Figure 8. pLI comparison of DNM and propagated genes from the

- 1317 **five submodules.** The probabilities of being loss of function intolerant (pLI) of genes
- 1318 from the five functional submodules are shown, derived from 46 damaging DNMs and 51
- 1319 propagated genes. Black thick line: median, Box: 1st and 3rd quantiles.





1321

1322 Extended Data Figure 9. The P168L patient mutation impairs TNK2 activity. a,

1323 P168L mutation is located within the kinase domain. TNK2 contains sterile alpha motif

1324 (SAM), Src homology 3 (SH3), CDS42, and RAC-interactive binding (CRIB), Mig6

1325 homology region (MHR), and ubiquitin-associated domain (UBA). **b**, Blots for the

1326 A156T kinase dead, wild-type, and the patient mutation P168L. Lysates were probed

1327 with pY284-Ack1 (top), Ack1-flag (middle), and gamma-tubulin (bottom).



Extended Data Figure 10. The H1149P patient mutation impairs TIAM1 activity. a,
H1149P mutation is located within the Dbl homology (DH) domain responsible for GEF

activity. TIAM1 contains an N-terminal pleckstrin homology (PH), coiled-coiled (CC),
 extension (Ex), RAS binding (RBD), PDZ, Dbl-homology (DH) and PH domains, with

1333 the patient mutation falling within the DH domain. **b**, Construct expression H1149P is

equivalent to wildtype in Phalloidin quantification. **c-d**, Construct expression H1149P in

1335 (c) basal and (d) constitutive active (C.A.) Src Rac1 Förster resonance energy transfer

1336 (FRET) is equivalent to wildtype. e, Protein expression H1149P in C.A. Src Rac1 FRET

1337 is equivalent to wildtype. Bar: mean, Errorbar: standard deviation of mean (SEM).

1338 Kruskal-Wallis followed by a pairwise Wilcoxon test, *P* value adjusted with Bonferroni.

1339 Data shown with Hampel filter.





1341 1342

1343 Extended Data Figure 11. VWA8b patient mutation R230G significantly reduces

protein expression levels. a, Schematic of protein domains for VWA8b consisting of
NTPase, Walker A (WA), ATP binding, and Walker B (WB) domain and patient
mutation R230G in the NTPase domain. b, Western blot for HA-tagged mVwa8b empty
water (EV) wildture and a P230G protein overexpressed in HEK203T calls and stained

1347 vector (EV), wildtype and p.R230G protein overexpressed in HEK293T cells and stained

- 1348 for HA and alpha tubulin as loading control. **c**, Quantification of HA band intensity from 1349 panel **b** normalized to loading control. Bar: mean, Errorbar: standard deviation of mean
- 1350 (SEM). one-way ANOVA ****: P value < 0.0001.
- 1351



1352 1353 Extended Data Figure 12. The R349C patient mutation in CLIP2 has no observable 1354 effect on microtubule dynamics. a, Domains in CLIP2 protein, microtubule associated domain (MBD), serine rich region containing the R349C patient mutation, and coiled coil 1355 1356 domain. b, GFP fused CLIP2 expression in HEK293T cells for wildtype (WT) and two 1357 synonymous codons (TGC and TGT both encoding for CYS) for R349C patient 1358 mutation. No notable difference in the level of expression was detected between the WT 1359 and the mutants. Experiments included co-transfection with constitutively active AKT 1360 E17K, a presumed upstream kinase of nearby S352. c-f, While at a low expression level 1361 in HuH7 cells, fluorescent CLIP2 is restricted to growing microtubule plus ends as 1362 expected (not shown), (c) its mild overexpression highlights the whole microtubule 1363 bodies without difference between WT, R349C (TGC) and a putative phosphorylation 1364 site, S352A (Scale bar 10µm). This condition allowed the measurement of a complete 1365 panel of microtubule dynamic instability parameters: (d) growth and shrinkage speed, (e) 1366 catastrophe and rescue (R) frequencies (f) the time spent in pause. There was no 1367 statistical difference between CLIP2 WT and the mutants. The values were measured

from at least 125 microtubules (25 cells) per condition. n = 3 independent experiments.



1372 1373

1368

1374 Extended Data Figure 13. BRSK2 patient mutation R620H shows no notable defects

1375 in kinase activity across known downstream phosphorylation targets. a, R620H

1376 mutation is located within the kinase associated 1 domain (KA1). BRSK2 also contains a

1377 kinase domain, Ubiquitin-associated (UBA), Proline rich region (Pro R). b, Western blot

1378 showing phosphorylation of AMPK substrate motifs observed across wildtype (WT),

kinase dead mutant control (K48A) and patient mutation (R620H) Flag-tagged BRSK2
when expressed in HEK293T cells. K48A has an average reduced intensity that is not

- 1381 observed in R620H. **c**, Western Blots of total and phosphorylated mTOR, S6K and
- 4EBP1 substrates showing no notable differences in phosphorylation for patient mutation
- 1383 R620H.



1384 1385

1386 Extended Data Figure 14. *PLCE1* patient mutation E623Q does not lead to

diminished Rho GTPase activity. a. Schematic of PLCE1 protein with domains 1387 1388 annotated. Patient E623Q mutation is located in the Ras GEF domain. PLCE1 contains a 1389 Guanine nucleotide exchange factor for Ras-like small GTPases (RAS GEF), Pleckstrin 1390 Homology (PH), Phospholipase C catalytic domain X (PLCX), Phospholipase C catalytic 1391 domain Y (PLCY), Protein Kinase C conserved region 2 (C2), RAS association domain 1 1392 (RA1), and RAS association domain 2 (RA2). b, Active GTP-bound forms of RAC1 and 1393 CDC42 precipitated from HEK293 expressing Myc-tagged PLCE1 using a GST-PAK1 1394 pulldown assay (n=4). Five percent input represents the controls for equal loading.

1395 Compared to mock cells, overexpression of wild-type (WT) and variant forms of PLCE1

- 1396 exhibited no significant difference in RAC1 and CDC42 activity. c-d, Quantifications of
- 1397 (c) RAC1 and (b) CDC42. e, Active GTP-bound form of RHOA precipitated from
- 1398 HEK293 expressing Myc-tagged PLCE1 using a GST-rhotekin pulldown assay.
- 1399 Overexpression of WT PLCE1 resulted in a substantial decrease in relative RHOA
- 1400 activity compared with mock cells. Compared to WT, cells transfected with variant forms
- 1401 of PLCE1 exhibited no significant differences in GTP-bound RHOA. f, Quantification of
- 1402 RHOA (n=4). Data were analyzed by one-way ANOVA with post hoc Bonferroni
- 1403 correction. Error bars: standard deviation for greater than 3 independent experiments. PD;
- 1404 pulldown, ** P < 0.01, n.s. not significant.



1405

1406 Extended Data Fig. 15. Validation of Whamm morpholino antisense oligonucleotide 1407 (MO). a, RT-PCR validates the effective disruption of splicing following injection of 1408 Whamm MO. b-d, The neural tube closure defect phenotype induced by Whamm MO 1409 (10 ng) was rescued through the injection of Whamm mRNA (700 pg). Embryos injected 1410 only with mRNA showed no significant phenotype. **b**, Dorsal views of Xenopus embryos 1411 at Stage 19 c, Embryos subjected to in situ hybridization against Pax3 to visualize the 1412 neural folds d, Graph depicting the quantitative analysis of the distance between neural 1413 folds. P-values by one-way ANOVA with post-hoc honestly significant difference (HSD) test. ****: *P* value < 0.0001, ns: not significant. 1414

- 1415
- 1416



$\begin{array}{c} 1417\\ 1418 \end{array}$

1419 Extended Data Figure 16. Pipeline of detecting high-confidence de novo mutation

1420 (DNM)s and annotation of D-Mis-HC. a, Schematic overview of DNM detection. The 1421 raw coverages of aligned bam files were utilized in consensus region generation (see 1422 Methods). Germline variants were utilized to test the integrity of the trios with 1423 TRUFFLE. GATK genotype refinement workflow was utilized for the DNM detection **b**, 1424 The candidate de novo SNVs and Indels were applied with a series of qualitative and 1425 quantitative filters. DP: depth, Binom: binomial test, alt: count of reads with alternative alleles, GQ: genotype quality, MQ: mapping quality, VQSR: variant quality score 1426 1427 recalibration, GT: genotype. c-d, Pathogenicity prediction of D-Mis-HC variants with 1428 MetaLR and REVEL. The pathogenicity of 116 D-Mis DNMs predicted by MetaSVM 1429 are shown with the prediction results from MetaLR and REVEL. (c) MetaLR deleterious 1430 (score > 0.5) is shown in triangle and (d) mutations with REVEL score higher than 0.75 1431 are predicted as deleterious (right).

1432 Extended Data Table

Mutation type	Category	Coding	Noncoding	Total
	DNM count	1,976	8,817	10793
SNV + Indel	DNM count per proband	20.16	89.97	110.13
	rate (× 10 ⁻⁸)	0.315	1.4	1.72
	DNM count	1,658	7,429	9,087
SNV	DNM count per proband	16.92	75.81	92.72
	rate (× 10 ⁻⁸)	0.26	1.18	1.45
	DNM count	318	1,388	1,706
Indel	DNM count per proband	3.24	14.16	17.41
	rate (× 10 ⁻⁸)	0.05	0.22	0.27

1433 Extended Data Table 1. De novo SNV and Indel rates (×10⁻⁸) of WGS in coding and

1434 **noncoding regions.** Rates were calculated with 99 trios could be analyzed after removal

1435 of four kinship failed trios.

Family	Chromosome	Start position	End position	Length	Variant type	Cytoband
7646	chr22	20,400,001	21,100,001	-700,000	Deletion	q11.21
7647	chr15	72,700,001	75,800,001	-3,100,000	Deletion	q24.2-q24.1
7662	chr15	30,600,001	32,100,001	1,500,000	Duplication	q13.3-q13.2
8469	chr21	13,900,001	43,000,001	28,900,000	Duplication	q22.11-q22.12

1437 Extended Data Table 2. de novo large CNV (>100kb) in WGS, analyzed with 99
1438 trios.

1439

Term	Ontology Source	ID	P Value (Bonferroni step-down adjusted)	% Associated Genes	Nr. Genes	Associated Genes
Morphogenesis of a polarized epithelium	GO Biological Process	GO:0001738	0.00001	8.41	9.00	BRSK2, CELSR1, CELSR2, GRHL3, LAMA3, SCRIB, SH3BP1, SMURF2, TIAM1
Signaling by NTRKs	Reactome	R-HSA:166520	0.00031	5.97	8.00	CLTC, DNM3, EP300, IRS1, PTPRS, RPS6KA2, TCF12, TIAM1
Establishment of planar polarity	GO Biological Process	GO:0001736	0.00070	7.41	6.00	BRSK2, CELSR1, CELSR2, GRHL3, SMURF2, TIAM1
Wnt signaling pathway, planar cell polarity pathway	GO Biological Process	GO:0060071	0.00100	8.62	5.00	CELSR1, CELSR2, GRHL3, SMURF2, TIAM1
L1CAM interactions	Reactome	R-HSA:373760	0.00220	5.04	6.00	CLTC, CNTNAP1, DCX, DNM3, DPYSL2, RPS6KA2
Signaling by NTRK1 (TRKA)	Reactome	R-HSA:187037	0.00276	5.22	6.00	CLTC, DNM3, EP300, IRS1, RPS6KA2, TCF12
Neural tube closure	GO Biological Process	GO:0001843	0.00323	4.90	5.00	CELSR1, GRHL2, GRHL3, SCRIB, TBXT

1440 Extended Data Table 3. Pathway enrichment of the damaging DNMs in MM. 187

1441 damaging DNMs (LGD + D-Mis) were tested for enrichment in known functional

1442 biological pathways in Gene ontology (GO) Biological Process, Reactome, and KEGG

1443 pathways. Pathways that were significant with Bonferroni step-down adjusted P value <

1444 0.05 are shown.

1445 Supplementary Table

Family ID	Gene	Mutation	OMIM associated phenotype	Mutations reported with OMIM phenotype	Patient phenotype
5875	KIF22	chr16:29798687C >T; c.484C>T; p.Arg162Ter	Spondyloepimetaphyseal dysplasia s. with joint laxity, type 2	Heterozygous missense in exon 4	Excluded Spondyloepimetaphyseal dysplasia features
6032	CELSR1	chr22:46397819G >GTTGGT; c.5551_5555dup; p.Asn1852LysfsT er7	Lymphatic malformation 9 s.	Heterozygous nonsense or frameshift show incomplete penetrance	Excluded lymphatic malformation features
6147	SLCO1B3- SLCO1B7	chr12:21067374C >T, c.1803C>T;p.Arg5 80X	Digenic recessive hyperbilirubinemia, Rotor type s.	Read through transcript	Excluded hyperbilirubinemia features
6293	TOP2B	chr3:25636033A> G, c.c.740T>C; p.Leu247Pro	B-cell immunodeficiency, distal limb anomalies, and urogenital malformation s.	Heterozygous deletion and missense mutations in the TOPRIM domain	Excluded immunodeficiency, limb and urogenital defect features
6307	ADGRB3	chr6:68975294G> A, c.1688G>A; p.Ser563Asn	Cerebellar ataxia	Biallelic loss	Excluded cerebellar ataxia features
6313	BICRA	chr19:47680692C >T, c.1522C>T; p.Gln508*	Coffin-Siris12 s.	Haploinsufficiency	Meets criteria for Coffin-Siris s.
6319	CLIP2	chr7:74357307C> T, c.1045C>T; p.Arg349Cys	Williams-Beuren s.	Contiguous gene deletion s. at 7q11.23	Excluded Williams-Beuren s. features
6328	SLC4A4	chr4:71472901C> A, c.1702C>A; Pro568Thr	Proximal renal tubular acidosis with ocular abnormalities s.	Biallelic substitutions lead to decrease NBC activity	Excluded renal tubular acidosis or ocular features. Displays growth retardation.
6337	TCF12	chr15:57262209G >T, c.412+1G>T; splice loss	Craniosynostosis type 3 s. Hypogonadotropic hypogonadism 26 s.	Haploinsufficiency; Biallelic loss of function	Displays features of craniosynostosis.
6388	LOXHD1	chr18:46509817T >G, c.2067-2A>C splice loss	Deafness, autosomal recessive type 77 s.	Biallelic mutations	Excluded features of deafness
6395	PLA2G7	chr6:46709351G> A, c.845C>T; p.Thr282lle	Platelet-activating factor acetylhydrolase deficiency s.	Biallelic mutations	Excluded features of platelet- activating factor acetylhydrolase deficiency
6423	KDM1A	chr1:23057487C> T, c.934C>T p.Arg312Cys	Cleft palate and distinctive facial features s.	Heterozygous loss	Lacks features of cleft palate
6570	TNK2	chr3:195872454A >T, c.1462T>A, p.Trp488Arg	Autosomal recessive infantile epilepsy (pending confirmation)	Biallelic loss	Excluded features of infantile epilepsy
6695	TIMM50	chr19:39485743A >G, c.109- 2318A>G;	3-methylglutaconic aciduria, type IX s.	Biallelic loss	Excluded features of 3- methylglutaconic aciduria

				-	-
		p.Tyr143Cys			
6705	ASPM	chr1:197102395T GAGA>T, c.6852_6855delT CTC; p.Leu2285Argfs*6	Microcephaly 5, primary, autosomal recessive s.	Biallelic loss	Excluded features of microcephaly
6708	SCAPER	chr15:76705971G >A, c.2179C>T; p.Arg727Ter	Intellectual developmental disorder and retinitis pigmentosa s.	Biallelic loss	Excluded features of intellectual disability or retinitis pigmentosa
6133	ZSWIM6	chr5:61541917C> T, c.2737C>T; p.Arg913Ter	Acromelic frontonasal dysostosis s.	Haploinsufficiency	Reduced size of nose, possible dysostosis
6289	UNC80	chr2:209872917C >T, c.3793C>T; p.Arg1265Ter	Hypotonia, infantile, with psychomotor retardation and characteristic facies 2 s.	Biallelic loss	Lacks typical facies, but has features of hypotonia
7443	POP1	chr8:98130062G> T, c.571G>T, p.Glu191Ter	Anauxetic dysplasia 2	Biallelic loss	Lacks features of anauxetic dysplasia
7437	DNAH5	chr5:13807727T> G, c.7753-2A>C, splice loss	Ciliary dyskinesia, primary, 3	Biallelic loss	Lacks features of ciliary dyskinesia
7440	ATXN7	chr3:63990756C> T, c.1579C>T; p.Arg527Trp	Spinocerebellar ataxia 7	CAG repeat expansion	Lacks features of spinocerebellar ataxia
8012	MED13L	chr12:115980836 G>A, c.5278C>T; p.Arg1760Ter	ID and distinctive facial features with or without cardiac defects (MRFACD)	Haploinsufficiency	Cannot exclude features of MRFACD.
8055	MMUT	chr6:49444675T> C, c.1640A>G; p.Asn547Ser	Methylmalonic aciduria, mut(0) type	Biallelic loss	Lacks features of methylmalonic aciduria
8012	NCKAP1L	chr12:54499380C >T, c.128C>T; p.Pro43Leu	Immunodeficiency 72 with autoinflammation	Biallelic loss	Lacks features of primary immunodeficiency
7859	VWA8	chr13:41729591T AG>T, c.2587_2588delC T; p.Leu863Sfs*20	Retinitis Pigmentosa 97(?)	Heterozygous missense	Lacks features of retinitis pigmentosa
7821	SPATA16	chr3:173019534C >T, c.800G>A; p.Arg267His	Spermatogenic failure 6 (?)	Biallelic loss	Unable to assess to due female sex
7749	SDHAF1	chr19:35995381T C>T, c.108delC; stop lost	Mitochondrial complex II deficiency, nuclear type 2	Biallelic loss	Lacks features of mitochondrial disease
7809	MYO6	chr6:75857131C> T, c.1258C>T; p.Arg420Cys	Deafness, nonsyndromic	Heterozygous missense	No evidence of deafness
7899	MAP2	chr2:209710227C >A, c.978C>A; Asn326Lys	Rett-like s. (preserved speech variant)	2q Contiguous gene deletion s.	Lacks Rett slike features
7886	ITPR3	chr6:33686219C> T, c.5834C>T; p.Thr1945lle	Charcot-Marie-Tooth disease, demyelinating, type 1J	Heterozygous missense	Lacks features of Charcot- Marie-Tooth disease
7922	GMPPB	chr3:49723293G> A, c.220C>T;	Muscular dystrophy- dystroglycanopathy (congenital with brain and eye anomalies), type A14	Biallelic loss	Excluded muscular dystrophy

		p.Arg74Ter			
7899	CAPN3	chr15:42411343G >C, c.2419G>C; p.Glu807Gln	Muscular dystrophy, limb-girdle, autosomal dominant 4	Heterozygous deletion	Excluded muscular dystrophy
7918	BSG	chr19:581510G>C , c.361G>C; pGly214Arg	Blood Group OK	Heterozygous missense	Not tested
7934	ASH1L	chr1:155479920G >A, c.2950C>T; p.Arg984Cys	Intellectual developmental disorder, autosomal dominant 52	Heterozygous missense	Cannot exclude intellectual disability
7803	ADGRV1	chr5:90811123C> A, c.2846C>A; p.Ala949Glu	Usher s: hearing loss and retinitis pigmentosa	Heterozygous loss (Febrile seizures)?, Biallelic loss (Usher s.)	No evidence of hearing or vision loss
7889	CUL3	chr2:224478199C >T, c.2175+1G>A; splice site lost	Pseudohypoaldosteronism, type IIE Neurodevelopmental disorder	Splice site variants (pseudohypoaldosteronism); Haploinsufficeincy (Neurodevelopmental disorder)	Cannot exclude neurodevelopmental disorder
7901	CNTNAP1	chr17:42690144T >G, c.1792T>G; p.Phe598CVal	Hypomyelinating neuropathy, congenital, 3; Lethal congenital contracture s. 7	Biallelic loss	Lacks features of hypomyelinating neuropathy or contractures
7905	DPYSL2	chr8:26644084A> C, c.1103A>C; p.Lys332Thr	Intellectual disability and dysmorphic features(?)	Heterozygous missense	Cannot exclude evidence for intellectual disability or dysmorphic features
7918	SCRIB	chr8:143803792C >T, c.3026G>A; p.Arg1091Gln	Craniorachischisis	Haploinsufficiency	Lacks features of craniorachischisis
7944	EP300	chr22:41178614T TCTC>T, c.6904_6907delT CTC:p.Leu2303Pr ofs*49	Menke-Hennekam s. 2, Rubinstein-Taybi s. 2	Heterozygous missense	Excluded Menke-Hennekam or Rubinstein-Taybi s.
7540	DHCR7	chr11:71435428A >G, c.1375T>C; p.Trp427Arg	Smith-Lemli-Opitz s.	Biallelic loss	Lacks Smith-Lemli-Opitz s. features
6293	TTC26	chr7:139189388C >T, c.1228C>T; p.Ara410Trp.	Blliary, renal, neurologic, and skeletal s.	Biallelic loss	Lacks biliary or renal features
7542	PLG	chr6:160722467C >T, c.1156C>T; p.Arg386Ter	Angioedema, dysplasminogemia, plasminogen deficiency	Heterozygous gain of function or biallelic loss	Lacks features of angioedema
7525	PCK2	chr14:24103719C >T, c.1276C>T; p.Arg426Trp	PEPCK deficiency, mitochondrial	Biallelic loss	Lacks features of hypoglycemia or liver
7546	LAMA3	chr18:23912880A >T, c.3923A>T; p.Asp1308Val	Epidermolysis bullosa	Biallelic loss	Lacks features of epidermolysis bullosa
5686	HECTD4	chr12:112179032: G>C, c.11256C>G; p.Tyr3752Ter	Neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum (NEDSSCC s.)	Biallelic loss	Excluded NEDSSCC s.
5801	TBXAS1	chr7:140015737C >A, c.1244C>A; p.Ala415Glu	Ghosal hematodiaphyseal s.	biallelic loss	Excluded Ghosal hematodiaphyseal s.
5343	PAX3	chr2:222232203G >A, c.667C>T; p.Arg223Ter	Waardenburg s.	Haploinsufficiency	Meets clinical criteria for Waardenburg s.
5655	MYBPC3	chr11:47349785G >A, c.643C>T;	Cardiomyopathy, dilated, 1MM Cardiomyopathy, hypertrophic,	Haploinsufficiency or biallelic loss	Excluded heart defect

		p.Arg215Cys	4 Left ventricular noncompaction 10		
5560	GRIA3	chrX:123417592T >C, c.1691T>C; p.lle564Thr	Intellectual developmental disorder, X-linked s., Wu type	Hemizygous mutations	Cannot exclude intellectual disability
5462	CYB561	chr17:63438215G T>G, c.13delA; Thr5Glnfs*8	Orthostatic hypotension 2	Biallelic loss	Lacks evidence for orthostasis
7218	ZSWIM6	chr5:61332835C>A, c.563C>A; p.Ala188Asp	Acromelic frontonasal dysostosis or NEDMAGA	Heterozygous p.R1163W or p.R913X missense	Excluded acromelic frontonasal dysostosis
6924	VWA8	chr13:41887322G> C, c.691C>G; p.Arg231Gly	Retinitis pigmentosa (?)	Heterozygous missense	Excluded retinitis pigmentosa
7164	VPS50	chr7:93291790G>T, c.1030G>T; p.Glu344Ter	Neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis	Biallelic loss	Excluded cholestasis
7073	VPS13C	chr15:61946374G> A, c.794C>T; p.Thr265lle	Parkinson disease 23, autosomal recessive, early onset	Biallelic loss	Excluded Parkinson disease
7226	TIAM1	chr21:31146924T> G, c.545A>C; p.His182Pro	Neurodevelopmental disorder with language delay and seizures (NEDLDS)	Biallelic loss	Cannot exclude neurodevelopmental delay
6972	SPEN	chr1:15928231AC> A, c.1992delC; p.Gln665Lysfs*144	Radio-tartalgia s.	Haploinsufficiency	Cannot exclude Radio- tartalgia s.
7227	POGZ	chr1:151406022G> A, c.2827C>T; p.Arg943Cys	White-Sutton s.	Haploinsufficiency	Cannot exclude features of White-Sutton s.
7158	PEX3	chr6:143489224T> C, c.1120T>C; p.*374Arg (Loss of stop codon)	Peroxisome biogensis disorder (Zellweger s.)	Biallelic loss	Excluded Zellweger s.
7223	KDM5B	chr1:202749126C> T, c.1700G>A; p.Arg567Gln	Intellectual developmental disorder, autosomal recessive 65	Biallelic loss	Cannot exclude intellectual disability
7013	IRS1	chr2:226796947G> GC, c.1791_1792insG;p. His598Alafs*13	Type 2 diabetes mellitus, susceptibility to	Haploinsufficiency	Excluded type 2 diabetes
7217	IRS1	chr2:226796947G> GC, c.1791_1792insG;p. His598Alafs*13	Type 2 diabetes mellitus, susceptibility to	Haploinsufficiency	Excluded type 2 diabetes
7191	GRHL2	chr8:101619557T> C; c.1448T>C; p.Cys373Arg	Corneal dystrophy, Deafness, autosomal dominant 28, Ectodermal dysplasia/short	Heterozygous (corneal dystrophy, deafness); homozygous (ectodermal	Excluded corneal dystrophy, deafness or ectodermal dysplasia

			stature s.	dysplasia)	
7119	FREM1	chr9:14801790T>G, c.3556A>C; p.Ser1186Arg	Bifid nose with or without anorectal and renal anomalies; Manitoba oculotrichoanal s.; Trigonocephaly type 2	Biallelic loss; Haploinsufficeincy; (Tigonocephaly only)	Cannot exclude trigonocephaly
6985	FEM1C	chr5:115524327A> G, c.1835T>C; p.Phe612Ser	Developmental delay, pyramidal signs, and limb ataxia (?)	Heterozygous missense	Cannot exclude developmental delay
7202	DCX	chrX:111401096T> C, c.599A>G; p.Asn200Ser	Subcortical laminar heterotopia	Heterozygous missense	Cannot exclude features of subcortical laminar heterotopia
7002	DAG1	chr3:49531270G>G A, c.759_760insA; p.Asn254Lysfs*20	Muscular dystrophy- dystroglycanopathy	Biallelic loss	Lacks features of muscular dystrophy
7071	CLTC	chr17:59666977G> A, c.2140G>A; p.Gly714Ser	Intellectual developmental disorder, autosomal dominant 56	Haploinsufficiency	Cannot exclude intellectual disability
6966	BRAT1	chr7:2543876C>T, c.369G>A; p.Trp123Ter	Neurodevelopmental disorder with cerebellar atrophy and with or without seizures; rigidity and multifocal seizure s.	Biallelic loss	Lacks features of cerebellar atrophy or seizures
6950	ADRA2B	chr2:96115933C>G , c.217G>C; p.Glu73Gln	Epilepsy, familial adult myoclonic	Heterozygous in frame insertion/deletion	Cannot exclude myoclonic epilepsy
7123	LEMD3	chr12:65169828GC CGCGGGACCAGC >G, c.233_245delCCGC GGGACCAGC; p.Arg78Glyfs*101	Buschke-Ollendorff s. Osteopoikilosis with or without melorheostosis	Heterozygous deletion/insertion, duplication, frameshift, missense	Cannot exclude Buschke- Ollendorff s.
7155	ТВХТ	chr6:166160836, c.1034+1G>C Loss of splice site	Sacral agenesis with vertebral anomalies	Biallelic loss	Lacks features of sacral agenesis
7157	UBIAD1	chr1:11285729C>G , c.258C>G; p.lle86Met	Corneal dystrophy, Schnyder type	Haploinsufficiency	Lacks features of corneal dystrophy
5943	SQOR	chr15:45661973A> G, c.253A>G; p.lle85Val	Sulfide quinone oxidoreductase deficiency	Biallelic loss	Lacks features of sulfide:quinone oxidoreductase deficiency
5980	SEC31A	chr4:82854963:TC> T, c.1146delG; p.Trp382Ter	Halperin-Birk s.	Biallelic loss	Excluded Halperin-Birk s.
6686	KRT83	chr12:52314788C> A, c.1325G>T; p.Cys442Phe	Erythrokeratodermia variabilis et progressiva 5	Biallelic loss (Erythrokeratodermia); Haploinsufficiency (Monilethrix)	Lacks skin defects

6692	HR	chr8:22120753C>A, c.2573G>T; p.Gly858Val	Alopecia universalis Atrichia with papular lesions	Biallelic loss	Lacks features of alopecia universalis
6707	DNAH11	chr7:21801213A>C, c.10310A>C; p.Glu3368Ala	Ciliary dyskinesia, primary, 7, with or without situs inversus	Biallelic loss	Lacks features of ciliary dyskinesia or situs inversus
8867	PREPL	chr2:44339179G>C , c.670C>G; p.Leu224Val	Myasthenic s, congenital, 22	Biallelic loss	Lacks features of myasthenia
8828	PAX3	chr2:222297081G >T, c.218C>A; p.Ser73Ter	Waardenburg s.	Haploinsufficiency	Meets criteria for Waardenburg s.
8828	INF2	chr14:104713537 C>T, c.2971C>T, p.Arg991Trp	Charcot-Marie-Tooth disease, dominant intermediate E with Glomerulosclerosis, focal segmental, 5	Haploinsufficiency	Excluded Charcot-Marie- Tooth or glomerulosclerosis
8861	GRHL3	chr1:24342238, c.892C>T; p.Arg298Cys	van der Woude s. type 2	Haploinsufficiency	Cannot exclude van der Woude s. type 2

1446 Supplementary Table 1. Phenotypic expansion of MM genes with DNM displaying

1447 syndrome and/or non syndrome disease features other than MM. Column 1: Family

number, Column 2: mutated gene, Column 3: Mutation identified for that gene and patient

in our cohort, Column 4: Relevant OMIM entry for each gene. Column 5: type of

1450 mutation reported in OMIM leading to phenotype. Column 6: Evidence for or against

1451 concordance with the OMIM phenotype. Genomic coordinates are in hg38. s.: syndrome,

1452 question mark (?): association remains uncertain according to OMIM.

1453 Supplementary Notes

1454

1455 *Power calculations for effect size*

To determine the adequate cohort size for identification of recurrently mutated genes in 1456 1457 MM, we developed a computational model and power calculations to estimate effect 1458 size^{77,78}. We first determined that with a sample size of 350 trios, observing such 1459 recurrence in two families would be significant genome-wide, with P value = 0.003, and 1460 from this calculated the false-discovery rate (FDR), assuming a baseline DNM rate 1461 among the $\sim 20,000$ human genes (Extended Data Fig. 1 gray dashed line). Then, 1462 leveraging data from a small NTD WES study in which DNM LOF mutations were 1463 identified in 20% of subjects, 34, and estimating that about 0.4% (i.e. 80/20,000) of gene 1464 knockouts in mouse show a MM-like phenotype, we estimate that there are 50–100 MM disease genes (k) to be discovered. Borrowing from previous literature 13,21,79 , we 1465 anticipate that LOF variants will be enriched in patients vs. controls with a v ratio 1466 1467 between 1.5 and 2.5. We ran 10,000 iterations to estimate the number of genes we will 1468 discover for various cohort sizes ranging from 100–1000 trios (Extended Data Fig. 1). 1469 For instance, with a cohort size of 400, if there are 50 genes to discover (i.e. k = 50) and 1470 with 2.5 times as many LOF variants in patients vs. control (i.e. v = 2.5), we expect ~16 1471 recurrently mutated genes to emerge. For the same cohort, if k = 100 and v = 1.5, we 1472 expect to discover ~ 2 recurrently mutated genes. Given the recurrence found in the cohort 1473 of 43 trios ¹⁵, and our preliminary data, we anticipated our results will fall between these 1474 two scenarios. Notably, this model predicts that with 800 MM trios sequenced as we 1475 propose here, we expect to discover $\sim 5-10$ recurrently mutated MM genes.

1476

1477 Reproducible prediction of D-Mis-HC

To validate the high confidence damaging missense variant (D-Mis-HC) that was
originally called by MetaSVM, we also applied MetaLR and REVEL to the DNMs. The
D-Mis-HC was highly reproducible with the two additional annotation tools with
recommended thresholds, MetaLR score > 0.5 and REVEL > 0.75 (Extended Data Fig.
1482
16c-16d).

1483

1484 Parents' age of conception comparison

To confirm if the excessive DNM burden in MM compared to controls are independent from the ages of parents at the time of conception, we gathered dates of births from probands, fathers, and mothers. Trios that were able to track all information from three family members (MM: 79, control: 683) were collected, to compare the ages of conception of father and mother, with Wilcoxon rank-sum test. (two-sided). We could clearly confirm that both the ages of mothers and fathers in the MM cohort were

- significantly lower than those of controls (**Extended Data Fig. 2a**). Although the rate of de novo variants is known to be highly correlated with the age of parents, the excessive
- 1493 burden observed in our study is not derived from the difference of fathers' and mothers'
- 1494 age distribution.
- 1495

1496 WGS evaluation for DNMs contributing to MM risk

From 101 additional trios and 1 quartet, we observed comparable de novo SNV and Indel rates with WGS data (**Extended Data Table 1**). Among them, 13 LGD and 39 D-Mis

1499 coding DNMs were observed. Also, 9 splicing disrupting variants (SpliceAI maximum 1500 delta score larger than 0.9) and 41 possible pathogenic noncoding DNMs (GREEN-1501 VARAN level 4) were collected. However, there was no recurrent gene mutated within 1502 the WGS cohorts (see **Supplementary Data** for the full list of DNMs in WGS). Instead, 1503 three overlapped with damaging (LGD+D-Mis) DNMs with WES data were revealed: a

1504 stop-gain in KDM1A, a splice donor gain in ITPR3, and a variant in GRHL2 enhancer. 1505 We could find four de novo CNVs (> 100 kb) in WGS trios, four de novo deletions and

- 1506 duplications were observed (Extended Data Table 2). The large CNVs were confirmed 1507 with the parents' sequence data (Extended Data Fig. 3b) and the duplicated or deleted
- 1508 regions were not recurrent. No de novo translocation or inversion was observed.
- 1509

1510 Multiplexed Error Robust In Situ Hybridization (MERFISH) spatial transcriptomic 1511 expression pattern of a subset of DNM genes

1512 We conducted Multiplexed Error Robust Fluorescent In Situ Hybridization (MERFISH)

- on the Vizgen platform using the methodology as described in Methods⁶⁴. We segmented 1513
- 1514 a total of 352,729 cells with uniform transcript density using cell segmentation. A subset
- 1515 of cells was excluded due to outlier cell volume (n = 9.922) or transcript density (n =
- 1516 21,319), with the remaining cells divided into 63 distinct clusters based on gene 1517
- expression using the Leiden algorithm, stratifying into 7 major cell types (Neuron, Neural 1518 crest, Neural Progenitor, Dorsal Root Ganglia, Pre epithelial to mesenchymal transition
- 1519 neural Crest progenitor, Mesoderm and Blood) in mouse E9.5 parasagittal sections. Cell
- 1520 types were defined by expression of marker genes selected based on previously published
- single cell transcriptomic studies⁶⁵⁻⁶⁷, employing ScType⁸⁰ for unbiased cell typing from 1521
- marker gene expression. Approximately 14% cells were flagged as 'indeterminate' type 1522
- 1523 that could not be clearly categorized, likely due either to a state of transitioning between cell types or lacking expression of marker genes. We selected 36 DNM genes identified
- 1524 1525 in MM subjects for multiplex spatial co-expression analysis (Extended Data Fig. 4). Percentage of gene expression vs cell type revealed that most of the candidate DNM 1526 1527 genes show expression in multiple cell types during neural tube closure. There were some 1528 genes like *Rnd2* and *Add2* that were expressed predominantly in neural cells, *Celsr1* in 1529 neural progenitor, Stabl in pre-EMT-neural precursor cells, Opalin expressed in predominantly in blood (Extended Data Fig. 5).
- 1530

1531 1532 Additional evidence for role of functionally implicated DNM genes in NTDs

1533 The DNM genes in which the DNM mutation impairs protein function showed additional 1534 prior evidence that may suggest a role in human NTDs. TIAM1, which promotes actin assembly via the Arp2/3 complex⁸¹, is essential for neural tube closure in mice⁸², but not 1535 1536 previously implicated in human NTD. TNK2, also known as ACK1 is a kinase associated 1537 with CDC42 that controls cellular protrusions associated with spinal neurulation in 1538 mouse³². VWA8 is a mitochondrial matrix-targeting ATPase, and notably mitochondrial dysfunction is implicated in both genetic and environmental murine models of NTD^{49,83}. 1539

1540

1541 Clinical phenotypes of patients compared to OMIM

- 1542 We assessed possible connections between DNM genes and associated OMIM
- 1543 phenotypes by recontacting subjects to inquire about clinical features listed in OMIM but
- 1544 possibly not described at the time of enrollment into our study. Resources used were

1545 Online Mendelian Inheritance in Man (OMIM), ClinVar, and PubMed. Out of the 192 1546 DNMs found in our cohort 82 were found to have other OMIM phenotypes (43.8%). Genes found to have other OMIM phenotypes in individual families/subjects were further 1547 1548 reviewed regarding the type of mutation compared with those reported in the clinical 1549 literature and compared with clinical status (Supplementary Table 1). Information 1550 available at the time of enrollment was used for clinical correlation along with follow up 1551 with the families via telephone or zoom to specifically inquire about features related to 1552 the published OMIM phenotypes. For some subjects like 6695, the de novo mutation 1553 occurred in a gene showing only recessive inheritance (TIMM50), so it was not surprising 1554 that the MM subject carrying a DNM in the gene did not report features of the OMIM 1555 entry. But for other subjects like 6313, the DNM occurred in a gene with the same or similar zygosity, and the patient showed features that cannot be distinguished from the 1556 reported OMIM entry, in this case Coffin-Siris features (i.e. developmental disability, 1557 1558 abnormalities of the fifth (pinky) fingers or toes, and characteristic facial features), 1559 suggesting MM may be a phenotypic expansion of this syndrome.

1560

1561 Estimation of number of genes in DNM contributing to MM risk

The estimation was based on previous publication¹⁴. Briefly, the total number of risk-1562 associated genes (C) is calculated with the number of observed risk-associated mutations 1563 1564 (d = 192) and recurrent mutations (r = 5, PAX3, IRS1, ZSWIM6, BRSK2, and VWA8). 1565 Since 28.26% of the damaging DNMs (LGD + D-Mis) are contributing to the MM risk, dand r were normalized as 54.26 and 1.41. The number of observed risk-associated genes 1566 1567 is c and c_1 refers to the number of genes mutated once and the probability of a newly 1568 added mutation hitting a previously mutated gene (μ) could be calculated as follows. 1569 Considering the variation in effect size of individual DNMs are assumed to be 1 to 1570 minimize underestimation of set size, C could be estimated as 2,021 genes. 1571

$$c = d - r$$

1573 $c_1 = d - (2 \times r)$

1574
$$\mu = 1 - c_1/d$$

1575
$$C = \frac{c}{\mu} + (g^2 \times d \times (1 - \mu)/\mu)$$